{
 "set": "Round 3 blind benchmark answer keys (harder set)",
 "built": "2026-11-11",
 "rubric": "../RUBRIC.md (4 marks: figure, cites, source contains figure, as-of)",
 "keys": [
  {
   "id": "R3-01",
   "ticker": "LIDR",
   "category": "dilution",
   "answer": "$50.0 million: the full amount of the new At Market Issuance Sales Agreement dated September 15, 2026 (no sales through September 30, 2026). The prior A.G.P. ATM agreement (raised to $125 million; $70.4 million sold) was terminated on September 15, 2026.",
   "accepted_variants": [
    "$50 million",
    "$50.0 million",
    "50,000,000"
   ],
   "as_of": "September 30, 2026",
   "primary_source": [
    {
     "accession": "0000947871-26-000869",
     "form": "424B5",
     "filing_date": "2026-09-15",
     "url": "https://www.sec.gov/Archives/edgar/data/1818644/000094787126000869/ss6825293_424b5.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1818644/000094787126000869/",
     "role": "new ATM prospectus supplement"
    },
    {
     "accession": "0001437749-26-035565",
     "form": "10-Q",
     "filing_date": "2026-11-06",
     "url": "https://www.sec.gov/Archives/edgar/data/1818644/000143774926035565/lidr20260930_10q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1818644/000143774926035565/",
     "role": "Q3 10-Q"
    },
    {
     "accession": "0001437749-26-026354",
     "form": "10-Q",
     "filing_date": "2026-08-06",
     "url": "https://www.sec.gov/Archives/edgar/data/1818644/000143774926026354/lidr20260630_10q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1818644/000143774926026354/",
     "role": "trap: superseded Q2 figure"
    }
   ],
   "supporting_passage": "[0000947871-26-000869 424B5 2026-09-15] 3_424b5.htm FORM 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-296038 PROSPECTUS SUPPLEMENT ( To Prospectus dated September 15, 2026 ) AEYE, INC. Up to $50,000,000 Common Stock We have entered into an At Market Issuance Sales Agreement, or the sales agreement, with A.G.P./Alliance Global Partners, or A.G.P., on September  ||| [0001437749-26-035565 10-Q 2026-11-06] M Agreement to a new aggregate value offering of up to $ 125,000 , following multiple prior increases since the original agreement. The Prior ATM Agreement was terminated simultaneously with entry into the 2026 ATM Agreement (as defined below) on September 15, 2026. Prior to its termination, the Company sold 24,070,541 shares for gross proceeds totaling $ 70,412 . On September 15,  ||| [0001437749-26-035565 10-Q 2026-11-06] d of 36 months, and will pay a cash commission rate of up to 3.0 % of gross proceeds from the sale of Placement Shares sold pursuant to the 2026 ATM Agreement. No sales were made under the 2026 ATM Agreement through September 30, 2026. The Common Stock Purchase Agreement, Prior ATM Agreement, and the 2026 ATM Agreement are collectively referred to herein as the \u201cCommon Stock Purchase Agreeme ||| [0001437749-26-026354 10-Q 2026-08-06] 026, we had sold 24,070,541 shares under our at-the-market equity offering program with A.G.P. for aggregate gross proceeds of approximately $70.4 million, and approximately $54.6 million of capacity remained available under that program. Our weighted average shares outstanding increased from 19,125,970 for the three months ended June 30, 2025 to 45,915,091 for the three mont",
   "supporting_passages": [
    "[0000947871-26-000869 424B5 2026-09-15] 3_424b5.htm FORM 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-296038 PROSPECTUS SUPPLEMENT ( To Prospectus dated September 15, 2026 ) AEYE, INC. Up to $50,000,000 Common Stock We have entered into an At Market Issuance Sales Agreement, or the sales agreement, with A.G.P./Alliance Global Partners, or A.G.P., on September ",
    "[0001437749-26-035565 10-Q 2026-11-06] M Agreement to a new aggregate value offering of up to $ 125,000 , following multiple prior increases since the original agreement. The Prior ATM Agreement was terminated simultaneously with entry into the 2026 ATM Agreement (as defined below) on September 15, 2026. Prior to its termination, the Company sold 24,070,541 shares for gross proceeds totaling $ 70,412 . On September 15, ",
    "[0001437749-26-035565 10-Q 2026-11-06] d of 36 months, and will pay a cash commission rate of up to 3.0 % of gross proceeds from the sale of Placement Shares sold pursuant to the 2026 ATM Agreement. No sales were made under the 2026 ATM Agreement through September 30, 2026. The Common Stock Purchase Agreement, Prior ATM Agreement, and the 2026 ATM Agreement are collectively referred to herein as the \u201cCommon Stock Purchase Agreeme",
    "[0001437749-26-026354 10-Q 2026-08-06] 026, we had sold 24,070,541 shares under our at-the-market equity offering program with A.G.P. for aggregate gross proceeds of approximately $70.4 million, and approximately $54.6 million of capacity remained available under that program. Our weighted average shares outstanding increased from 19,125,970 for the three months ended June 30, 2025 to 45,915,091 for the three mont"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "The Q2 10-Q says $54.6 million remained under the prior agreement; that agreement was terminated and replaced mid-quarter, so carrying the $54.6 million forward (or adding $54.6m + $50m) is wrong.",
   "difficulty_features": [
    "superseded agreement",
    "multi-filing (424B5 + two 10-Qs)"
   ],
   "question": "As of September 30, 2026, how much capacity remained available under AEye, Inc.'s (LIDR) at-the-market equity program with A.G.P., and under which agreement?"
  },
  {
   "id": "R3-02",
   "ticker": "XXII",
   "category": "reverse_split",
   "answer": "Five reverse splits: 1-for-16 (effective April 2, 2024), 1-for-135 (December 17, 2024), 1-for-23 (June 20, 2025), 1-for-15 (January 26, 2026) and 1-for-20 (June 12, 2026). Cumulative factor 16 x 135 x 23 x 15 x 20 = 14,904,000 (i.e. 1-for-14,904,000).",
   "accepted_variants": [
    "5 reverse splits",
    "14,904,000",
    "1-for-14,904,000",
    "1:14,904,000"
   ],
   "as_of": "Window January 1, 2024 to October 31, 2026",
   "primary_source": [
    {
     "accession": "0001104659-24-043130",
     "form": "8-K",
     "filing_date": "2024-04-03",
     "url": "https://www.sec.gov/Archives/edgar/data/1347858/000110465924043130/tm2410716d1_8k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1347858/000110465924043130/",
     "role": "split 1"
    },
    {
     "accession": "0001104659-24-129440",
     "form": "8-K",
     "filing_date": "2024-12-17",
     "url": "https://www.sec.gov/Archives/edgar/data/1347858/000110465924129440/tm2431379d1_8k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1347858/000110465924129440/",
     "role": "split 2"
    },
    {
     "accession": "0001641172-25-015296",
     "form": "8-K",
     "filing_date": "2025-06-16",
     "url": "https://www.sec.gov/Archives/edgar/data/1347858/000164117225015296/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1347858/000164117225015296/",
     "role": "split 3"
    },
    {
     "accession": "0001493152-26-003185",
     "form": "8-K",
     "filing_date": "2026-01-22",
     "url": "https://www.sec.gov/Archives/edgar/data/1347858/000149315226003185/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1347858/000149315226003185/",
     "role": "split 4"
    },
    {
     "accession": "0001493152-26-027838",
     "form": "8-K",
     "filing_date": "2026-06-09",
     "url": "https://www.sec.gov/Archives/edgar/data/1347858/000149315226027838/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1347858/000149315226027838/",
     "role": "split 5"
    },
    {
     "accession": "0001493152-26-049743",
     "form": "8-K",
     "filing_date": "2026-11-03",
     "url": "https://www.sec.gov/Archives/edgar/data/1347858/000149315226049743/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1347858/000149315226049743/",
     "role": "trap: outside window"
    }
   ],
   "supporting_passage": "[0001104659-24-043130 8-K 2024-04-03]  filed a Certificate of Change (the \u201cCertificate\u201d) pursuant to Nevada Revised Statutes (\u201cNRS\u201d) with the Secretary of State of the State of Nevada authorizing a 1-for-16 reverse stock split of the Company\u2019s issued and outstanding shares of common stock, par value $0.00001 (the \u201cReverse Stock Split\u201d). There was no change to the  ||| [0001104659-24-043130 8-K 2024-04-03] pliance with). Effects of the Reverse Stock Split Effective Date; Symbol; CUSIP Number . The Reverse Stock Split became effective at 12:01 a.m. Eastern Time on April 2, 2024, and was reflected with NASDAQ and in the marketplace at the open of business on April 2, 2024 (the \u201cEffective Date\u201d), whereupon the shares of common stock beg ||| [0001104659-24-129440 8-K 2024-12-17] cate of Change (the \u201cCertificate\u201d) pursuant to Nevada Revised Statutes (\u201cNRS\u201d) Section 78.2055 with the Secretary of State of the State of Nevada authorizing a 1-for-135 reverse stock split of the Company\u2019s issued and outstanding shares of common stock (the \u201cReverse Stock Split\u201d). The stockholders of the Company previously appr ||| [0001104659-24-129440 8-K 2024-12-17]  the Hearings Panel. Consequently, the common stock will remain listed on Nasdaq at least until the Hearings Panel renders a decision following the hearing. On December 17, 2024, the Company completed a 1 for 135 reverse stock split to increase the trading price of the Company\u2019s common stock to cure the listing deficiencies noted above ||| [0001641172-25-015296 8-K 2025-06-16] icate of Change (the \u201cCertificate\u201d) pursuant to Nevada Revised Statutes (\u201cNRS\u201d) Section 78.209 with the Secretary of State of the State of Nevada authorizing a 1-for-23 reverse stock split of the Company\u2019s (a) authorized shares of common stock; and (b) issued and outstanding shares of common stock (the \u201cReverse Stock Split\u201d).  ||| [0001641172-25-015296 8-K 2025-06-16] NASDAQ\u201d). Effects of the Reverse Stock Split Effective Date; Symbol; CUSIP Number . The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on June 20, 2025, and will be reflected with NASDAQ and in the marketplace at the open of business on June 20, 2025 (the \u201cEffective Date\u201d), whereupon the shares of common stock ||| [0001493152-26-003185 8-K 2026-01-22] te of Amendment (the \u201cCertificate\u201d) pursuant to Nevada Revised Statutes (\u201cNRS\u201d) Section 78.209 with the Secretary of State of the State of Nevada authorizing a 1-for-15 reverse stock split of the Company\u2019s issued and outstanding shares of common stock (the \u201cReverse Stock Split\u201d). Reason for the Reverse Stock Split The Reverse  ||| [0001493152-26-003185 8-K 2026-01-22] NASDAQ\u201d). Effects of the Reverse Stock Split Effective Date; Symbol; CUSIP Number . The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on January 26, 2026, and will be reflected with NASDAQ and in the marketplace at the open of business on January 26, 2026 (the \u201cEffective Date\u201d), whereupon the shares of common st ||| [0001493152-26-027838 8-K 2026-06-09] f Amendment (the \u201c Certificate \u201d) pursuant to Nevada Revised Statutes (\u201c NRS \u201d) Section 78.209 with the Secretary of State of the State of Nevada authorizing a 1-for-20 reverse stock split of the Company\u2019s issued and outstanding shares of common stock (the \u201c Reverse Stock Split \u201d). Reason for the Reverse Stock Split The Reverse Stock Split was ef ||| [0001493152-26-027838 8-K 2026-06-09]  NASDAQ Capital Market (\u201c NASDAQ \u201d). Effects of the Reverse Stock Split Effective Date; Symbol; CUSIP Number . The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on June 12, 2026, and will be reflected with NASDAQ and in the marketplace at the open of business on June 12, 2026 (the \u201c Effective Date \u201d), whereupon the shares of common sto ||| [0001493152-26-049743 8-K 2026-11-03] te of Amendment (the \u201cCertificate\u201d) pursuant to Nevada Revised Statutes (\u201cNRS\u201d) Section 78.209 with the Secretary of State of the State of Nevada authorizing a 1-for-58 reverse stock split of the Company\u2019s issued and outstanding shares of common stock (the \u201cReverse Stock Split\u201d). Reason for the Reverse Stock Split The Reverse  ||| [0001493152-26-049743 8-K 2026-11-03] CAPITAL STOCK The Restated Articles of Incorporation are hereby amended by adding the following as a new paragraph to the end of section 4.1: \u201cAt 12:01 a.m. on November 5, 2026 (the \u201cEffective Time\u201d), each 58 shares of the Corporation\u2019s Common Stock issued and outstanding immediately prior to the Effective Time shall be reclassified a",
   "supporting_passages": [
    "[0001104659-24-043130 8-K 2024-04-03]  filed a Certificate of Change (the \u201cCertificate\u201d) pursuant to Nevada Revised Statutes (\u201cNRS\u201d) with the Secretary of State of the State of Nevada authorizing a 1-for-16 reverse stock split of the Company\u2019s issued and outstanding shares of common stock, par value $0.00001 (the \u201cReverse Stock Split\u201d). There was no change to the ",
    "[0001104659-24-043130 8-K 2024-04-03] pliance with). Effects of the Reverse Stock Split Effective Date; Symbol; CUSIP Number . The Reverse Stock Split became effective at 12:01 a.m. Eastern Time on April 2, 2024, and was reflected with NASDAQ and in the marketplace at the open of business on April 2, 2024 (the \u201cEffective Date\u201d), whereupon the shares of common stock beg",
    "[0001104659-24-129440 8-K 2024-12-17] cate of Change (the \u201cCertificate\u201d) pursuant to Nevada Revised Statutes (\u201cNRS\u201d) Section 78.2055 with the Secretary of State of the State of Nevada authorizing a 1-for-135 reverse stock split of the Company\u2019s issued and outstanding shares of common stock (the \u201cReverse Stock Split\u201d). The stockholders of the Company previously appr",
    "[0001104659-24-129440 8-K 2024-12-17]  the Hearings Panel. Consequently, the common stock will remain listed on Nasdaq at least until the Hearings Panel renders a decision following the hearing. On December 17, 2024, the Company completed a 1 for 135 reverse stock split to increase the trading price of the Company\u2019s common stock to cure the listing deficiencies noted above",
    "[0001641172-25-015296 8-K 2025-06-16] icate of Change (the \u201cCertificate\u201d) pursuant to Nevada Revised Statutes (\u201cNRS\u201d) Section 78.209 with the Secretary of State of the State of Nevada authorizing a 1-for-23 reverse stock split of the Company\u2019s (a) authorized shares of common stock; and (b) issued and outstanding shares of common stock (the \u201cReverse Stock Split\u201d). ",
    "[0001641172-25-015296 8-K 2025-06-16] NASDAQ\u201d). Effects of the Reverse Stock Split Effective Date; Symbol; CUSIP Number . The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on June 20, 2025, and will be reflected with NASDAQ and in the marketplace at the open of business on June 20, 2025 (the \u201cEffective Date\u201d), whereupon the shares of common stock",
    "[0001493152-26-003185 8-K 2026-01-22] te of Amendment (the \u201cCertificate\u201d) pursuant to Nevada Revised Statutes (\u201cNRS\u201d) Section 78.209 with the Secretary of State of the State of Nevada authorizing a 1-for-15 reverse stock split of the Company\u2019s issued and outstanding shares of common stock (the \u201cReverse Stock Split\u201d). Reason for the Reverse Stock Split The Reverse ",
    "[0001493152-26-003185 8-K 2026-01-22] NASDAQ\u201d). Effects of the Reverse Stock Split Effective Date; Symbol; CUSIP Number . The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on January 26, 2026, and will be reflected with NASDAQ and in the marketplace at the open of business on January 26, 2026 (the \u201cEffective Date\u201d), whereupon the shares of common st",
    "[0001493152-26-027838 8-K 2026-06-09] f Amendment (the \u201c Certificate \u201d) pursuant to Nevada Revised Statutes (\u201c NRS \u201d) Section 78.209 with the Secretary of State of the State of Nevada authorizing a 1-for-20 reverse stock split of the Company\u2019s issued and outstanding shares of common stock (the \u201c Reverse Stock Split \u201d). Reason for the Reverse Stock Split The Reverse Stock Split was ef",
    "[0001493152-26-027838 8-K 2026-06-09]  NASDAQ Capital Market (\u201c NASDAQ \u201d). Effects of the Reverse Stock Split Effective Date; Symbol; CUSIP Number . The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on June 12, 2026, and will be reflected with NASDAQ and in the marketplace at the open of business on June 12, 2026 (the \u201c Effective Date \u201d), whereupon the shares of common sto",
    "[0001493152-26-049743 8-K 2026-11-03] te of Amendment (the \u201cCertificate\u201d) pursuant to Nevada Revised Statutes (\u201cNRS\u201d) Section 78.209 with the Secretary of State of the State of Nevada authorizing a 1-for-58 reverse stock split of the Company\u2019s issued and outstanding shares of common stock (the \u201cReverse Stock Split\u201d). Reason for the Reverse Stock Split The Reverse ",
    "[0001493152-26-049743 8-K 2026-11-03] CAPITAL STOCK The Restated Articles of Incorporation are hereby amended by adding the following as a new paragraph to the end of section 4.1: \u201cAt 12:01 a.m. on November 5, 2026 (the \u201cEffective Time\u201d), each 58 shares of the Corporation\u2019s Common Stock issued and outstanding immediately prior to the Effective Time shall be reclassified a"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Five 8-Ks must be found and multiplied. Traps: a 1-for-58 split effective November 5, 2026 (8-K filed Nov 3, 2026) is AFTER the window and must be excluded (including it gives 864,432,000); a 1-for-15 split in July 2023 is BEFORE the window. Several other 2025-2026 8-Ks carry Item 5.03 without being splits.",
   "difficulty_features": [
    "multi-filing (5 filings)",
    "date-window exclusion",
    "arithmetic"
   ],
   "question": "How many reverse stock splits did 22nd Century Group (XXII) make effective between January 1, 2024 and October 31, 2026 (inclusive), what was each ratio, and what is the combined (cumulative) reverse-split factor over that window?"
  },
  {
   "id": "R3-03",
   "ticker": "EONR",
   "category": "cash",
   "answer": "$375,036 as of December 31, 2025 (FY2025 Form 10-K filed September 28, 2026). Its Q1 and Q2 2026 10-Qs were not filed until October 13 and October 22, 2026.",
   "accepted_variants": [
    "$375,036",
    "375,036",
    "$0.4 million"
   ],
   "as_of": "December 31, 2025 balance; reports filed on or before October 1, 2026",
   "primary_source": [
    {
     "accession": "0001213900-26-103762",
     "form": "10-K",
     "filing_date": "2026-09-28",
     "url": "https://www.sec.gov/Archives/edgar/data/1842556/000121390026103762/ea0285266-10k_eon.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1842556/000121390026103762/",
     "role": "10-K FY2025"
    }
   ],
   "supporting_passage": "[0001213900-26-103762 10-K 2026-09-28] ible notes payable, $200,000 from related party notes payable and $1,517,337 from merchant cash advances. A total of $1,617,337 of this is due within one year. As of December 31, 2025, we had $375,036 of cash and cash equivalents on hand and had a working capital deficit of $21,814,454. These conditions raise substantial doubt about our ability to continue as a going concern within one ",
   "supporting_passages": [
    "[0001213900-26-103762 10-K 2026-09-28] ible notes payable, $200,000 from related party notes payable and $1,517,337 from merchant cash advances. A total of $1,617,337 of this is due within one year. As of December 31, 2025, we had $375,036 of cash and cash equivalents on hand and had a working capital deficit of $21,814,454. These conditions raise substantial doubt about our ability to continue as a going concern within one "
   ],
   "xbrl_facts": [
    {
     "tag": "CashAndCashEquivalentsAtCarryingValue",
     "value": 375036,
     "period_start": null,
     "period_end": "2025-12-31",
     "accession": "0001213900-26-103762"
    },
    {
     "tag": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "value": 375036,
     "period_start": null,
     "period_end": "2025-12-31",
     "accession": "0001213900-26-103762"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Late filer: EONR filed NT 10-Qs for Q1 and Q2 2026 and only filed those 10-Qs after the as-of date (Oct 13 and Oct 22, 2026), plus a 10-K/A on Oct 13, 2026. A tool that grabs the newest 10-Q answers with a June 30, 2026 figure that did not exist on Oct 1, 2026.",
   "difficulty_features": [
    "as-of discipline (late filer)",
    "ignore later filings"
   ],
   "question": "Using only reports EON Resources (EONR) had filed with the SEC on or before October 1, 2026: what was the company's most recently reported balance-sheet cash and cash equivalents, and as of what date?"
  },
  {
   "id": "R3-04",
   "ticker": "ONFO",
   "category": "shares_float",
   "answer": "Cover: 2,452,712 shares outstanding as of August 19, 2026. Balance sheet: 150,462 shares at June 30, 2026 (10-Q for the quarter ended June 30, 2026).",
   "accepted_variants": [
    "2,452,712",
    "150,462"
   ],
   "as_of": "Cover date August 19, 2026; balance sheet June 30, 2026",
   "primary_source": [
    {
     "accession": "0001654954-26-007754",
     "form": "10-Q",
     "filing_date": "2026-08-19",
     "url": "https://www.sec.gov/Archives/edgar/data/1825452/000165495426007754/onfo_10q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1825452/000165495426007754/",
     "role": "Q2 2026 10-Q"
    }
   ],
   "supporting_passage": "[0001654954-26-007754 10-Q 2026-08-19] registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes \u2610 No \u2612 Number of shares of common stock outstanding as of August 19, 2026 was 2,452,712 . Page No. PART I. FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited) 4 Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025 4 Con ||| [0001654954-26-007754 10-Q 2026-08-19] ued and outstanding at June 30, 2026 and December 31, 2025, respectively 169 169 Common stock, $ 0.001 par value, 300,000,000 and 50,000,000 shares authorized, 150,462 and 117,264 issued and outstanding at June 30, 2026 and December 31, 2025, respectively 150 117 Additional paid-in capital 26,252,158 24,530,736 Accumulated other comprehensive income 92,546 91,110 Accumulated d",
   "supporting_passages": [
    "[0001654954-26-007754 10-Q 2026-08-19] registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes \u2610 No \u2612 Number of shares of common stock outstanding as of August 19, 2026 was 2,452,712 . Page No. PART I. FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited) 4 Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025 4 Con",
    "[0001654954-26-007754 10-Q 2026-08-19] ued and outstanding at June 30, 2026 and December 31, 2025, respectively 169 169 Common stock, $ 0.001 par value, 300,000,000 and 50,000,000 shares authorized, 150,462 and 117,264 issued and outstanding at June 30, 2026 and December 31, 2025, respectively 150 117 Additional paid-in capital 26,252,158 24,530,736 Accumulated other comprehensive income 92,546 91,110 Accumulated d"
   ],
   "xbrl_facts": [
    {
     "tag": "EntityCommonStockSharesOutstanding",
     "value": 2452712,
     "period_start": null,
     "period_end": "2026-08-19",
     "accession": "0001654954-26-007754"
    },
    {
     "tag": "CommonStockSharesIssued",
     "value": 150462,
     "period_start": null,
     "period_end": "2026-06-30",
     "accession": "0001654954-26-007754"
    },
    {
     "tag": "CommonStockSharesOutstanding",
     "value": 150462,
     "period_start": null,
     "period_end": "2026-06-30",
     "accession": "0001654954-26-007754"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "The two counts differ by 16.3x because of post-quarter issuance; a tool that reports only one, or treats the cover count as the quarter-end count, misses half the answer. A later Q3 10-Q filed after October 31, 2026 must not be used.",
   "difficulty_features": [
    "cover vs balance sheet",
    "as-of discipline"
   ],
   "question": "In the most recent Form 10-Q that Onfolio Holdings (ONFO) had filed on or before October 31, 2026, how many shares of common stock were outstanding as of the cover-page date, and how many were issued and outstanding on the balance sheet at the end of the quarter?"
  },
  {
   "id": "R3-05",
   "ticker": "RNXT",
   "category": "other_8k",
   "answer": "No. Nasdaq confirmed on August 20, 2026 that RNXT had regained compliance (closing bid at or above $1.00 for ten consecutive business days, August 6-19, 2026); the matter was closed. Its second compliance period had run to December 28, 2026.",
   "accepted_variants": [
    "regained compliance",
    "August 20, 2026"
   ],
   "as_of": "October 31, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-039472",
     "form": "8-K",
     "filing_date": "2026-08-20",
     "url": "https://www.sec.gov/Archives/edgar/data/1574094/000149315226039472/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1574094/000149315226039472/",
     "role": "compliance regained"
    },
    {
     "accession": "0001493152-26-031662",
     "form": "8-K",
     "filing_date": "2026-07-02",
     "url": "https://www.sec.gov/Archives/edgar/data/1574094/000149315226031662/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1574094/000149315226031662/",
     "role": "trap: superseded deadline"
    }
   ],
   "supporting_passage": "[0001493152-26-039472 8-K 2026-08-20] s days from August 6, 2026 through August 19, 2026, the closing bid price of the Common Stock had been $1.00 per share or greater. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement and Nasdaq considers the matter closed. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the u ||| [0001493152-26-039472 8-K 2026-08-20] on, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2026 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction (Commission (IRS Employer of i ||| [0001493152-26-031662 8-K 2026-07-02] et regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until December 28, 2026 (the \u201cSecond Compliance Period\u201d), to regain compliance. If at any time during the Second Compliance Period, the closing bid price of the Common Stock is at lea",
   "supporting_passages": [
    "[0001493152-26-039472 8-K 2026-08-20] s days from August 6, 2026 through August 19, 2026, the closing bid price of the Common Stock had been $1.00 per share or greater. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement and Nasdaq considers the matter closed. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the u",
    "[0001493152-26-039472 8-K 2026-08-20] on, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2026 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction (Commission (IRS Employer of i",
    "[0001493152-26-031662 8-K 2026-07-02] et regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until December 28, 2026 (the \u201cSecond Compliance Period\u201d), to regain compliance. If at any time during the Second Compliance Period, the closing bid price of the Common Stock is at lea"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "A July 2026 8-K granted a second compliance period to December 28, 2026; a tool reading only that filing answers 'deficient, deadline Dec 28, 2026'. The later August 8-K closes the matter.",
   "difficulty_features": [
    "superseded status",
    "multi-filing"
   ],
   "question": "As of October 31, 2026, was RenovoRx (RNXT) still out of compliance with Nasdaq's $1.00 minimum bid price requirement? If so, what was its deadline; if not, when did it regain compliance?"
  },
  {
   "id": "R3-06",
   "ticker": "CODX",
   "category": "dilution",
   "answer": "5,012,756 warrants outstanding in total (15,500 2021 acquisition warrants + 1,592,532 May 2026 warrants + 3,404,724 July 2026 inducement warrants). 1,592,532 May 2026 warrants remained (3,294,894 issued, 1,702,362 exercised in the July/August 2026 inducement).",
   "accepted_variants": [
    "5,012,756",
    "1,592,532"
   ],
   "as_of": "September 30, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-050963",
     "form": "10-Q",
     "filing_date": "2026-11-10",
     "url": "https://www.sec.gov/Archives/edgar/data/1692415/000149315226050963/form10-q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1692415/000149315226050963/",
     "role": "Q3 10-Q"
    },
    {
     "accession": "0001493152-26-035553",
     "form": "8-K",
     "filing_date": "2026-07-31",
     "url": "https://www.sec.gov/Archives/edgar/data/1692415/000149315226035553/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1692415/000149315226035553/",
     "role": "inducement 8-K"
    }
   ],
   "supporting_passage": "[0001493152-26-050963 10-Q 2026-11-10] rfeited/Cancelled - - - - Exercised - ( 1,592,532 ) ( 1,702,362 ) - Outstanding at September 30, 2026 15,500 - 1,592,532 3,404,724 15 As of September 30, 2026, the Company had 5,012,756 common stock purchase warrants outstanding, of which 3,404,724 were not exercisable pending receipt of shareholder approval required under applicable Nasdaq rules. The exercise of the 15,500 warrants is ||| [0001493152-26-050963 10-Q 2026-11-10] eighted-Average Number of Weighted-Average Remaining Contractual Warrants Exercise Price Life (in Years) 2021 Acquisition Related Warrants 15,500 $ 273.75 0.26 May 2026 Warrants 1,592,532 $ 1.57 4.70 July 2026 Warrants 3,404,724 $ 1.56 5.19 December 31, 2025 Weighted-Average Number of Weighted-Average Remaining Contractual Warrants Exercise Pric ||| [0001493152-26-035553 8-K 2026-07-31] cement agreement (the \u201cInducement Letter\u201d) with certain holders (the \u201cHolders\u201d) of certain of the Company\u2019s existing warrants to purchase up to an aggregate of 1,702,362 shares of the Company\u2019s common stock originally issued on May 21, 2026, with a five-year term at an exercise price of $1.571 per share (the \u201cExisting Warrants\u201d",
   "supporting_passages": [
    "[0001493152-26-050963 10-Q 2026-11-10] rfeited/Cancelled - - - - Exercised - ( 1,592,532 ) ( 1,702,362 ) - Outstanding at September 30, 2026 15,500 - 1,592,532 3,404,724 15 As of September 30, 2026, the Company had 5,012,756 common stock purchase warrants outstanding, of which 3,404,724 were not exercisable pending receipt of shareholder approval required under applicable Nasdaq rules. The exercise of the 15,500 warrants is",
    "[0001493152-26-050963 10-Q 2026-11-10] eighted-Average Number of Weighted-Average Remaining Contractual Warrants Exercise Price Life (in Years) 2021 Acquisition Related Warrants 15,500 $ 273.75 0.26 May 2026 Warrants 1,592,532 $ 1.57 4.70 July 2026 Warrants 3,404,724 $ 1.56 5.19 December 31, 2025 Weighted-Average Number of Weighted-Average Remaining Contractual Warrants Exercise Pric",
    "[0001493152-26-035553 8-K 2026-07-31] cement agreement (the \u201cInducement Letter\u201d) with certain holders (the \u201cHolders\u201d) of certain of the Company\u2019s existing warrants to purchase up to an aggregate of 1,702,362 shares of the Company\u2019s common stock originally issued on May 21, 2026, with a five-year term at an exercise price of $1.571 per share (the \u201cExisting Warrants\u201d"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "The July 30, 2026 inducement 8-K reads as if all May warrants (1,702,362) were exercised; in fact 3,294,894 were issued and 1,592,532 remain. The 1,592,532 figure also coincides with the May pre-funded warrants (all exercised), and the 3,404,724 new warrants were not yet exercisable pending shareholder approval but are still outstanding.",
   "difficulty_features": [
    "footnote table",
    "event in later 8-K",
    "look-alike numbers"
   ],
   "question": "As of September 30, 2026, how many common stock purchase warrants did Co-Diagnostics (CODX) have outstanding in total, and how many of the warrants issued in its May 2026 private placement were still outstanding?"
  },
  {
   "id": "R3-07",
   "ticker": "JAGX",
   "category": "reverse_split",
   "answer": "Four: 1-for-60 (effective May 23, 2024), 1-for-25 (March 24, 2025), 1-for-35 (April 30, 2026) and 1-for-15 (September 17, 2026). Cumulative factor 60 x 25 x 35 x 15 = 787,500 (1-for-787,500).",
   "accepted_variants": [
    "4 reverse splits",
    "787,500",
    "1-for-787,500"
   ],
   "as_of": "Window January 1, 2024 to October 31, 2026",
   "primary_source": [
    {
     "accession": "0001104659-24-064484",
     "form": "8-K",
     "filing_date": "2024-05-23",
     "url": "https://www.sec.gov/Archives/edgar/data/1585608/000110465924064484/tm2415080d1_8k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1585608/000110465924064484/",
     "role": "split 1"
    },
    {
     "accession": "0000950170-25-040784",
     "form": "8-K",
     "filing_date": "2025-03-18",
     "url": "https://www.sec.gov/Archives/edgar/data/1585608/000095017025040784/jagx-20250318.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1585608/000095017025040784/",
     "role": "split 2"
    },
    {
     "accession": "0001193125-26-179391",
     "form": "8-K",
     "filing_date": "2026-04-27",
     "url": "https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/d109088d8k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/",
     "role": "split 3"
    },
    {
     "accession": "0001193125-26-391415",
     "form": "8-K",
     "filing_date": "2026-09-15",
     "url": "https://www.sec.gov/Archives/edgar/data/1585608/000119312526391415/d105876d8k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1585608/000119312526391415/",
     "role": "split 4"
    }
   ],
   "supporting_passage": "[0001104659-24-064484 8-K 2024-05-23] ompany\u2019s board of directors (the \u201cBoard\u201d) on or before January 22, 2025. Pursuant to such authority granted by the Company\u2019s stockholders, the Board approved a one-for-sixty (60) reverse stock split (the \u201cReverse Stock Split\u201d) of the Common Stock , and on May 17, 2024, the Company filed the Eighth Amendment with the Secretary of State of the State of Delaw ||| [0001104659-24-064484 8-K 2024-05-23]  exchange on which registered Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital Market Item 1.01 Entry into a Material Definitive Agreement. On May 23, 2024, Jaguar Health, Inc. (the \u201cCompany\u201d) entered into an amendment (the \u201cSecond ATM Amendment\u201d) to that certain At the Market Offering Agreement, dated December 10 ||| [0000950170-25-040784 8-K 2025-03-18]  Company\u2019s board of directors (the \u201cBoard\u201d) on or before March 13, 2026. Pursuant to such authority granted by the Company\u2019s stockholders, the Board approved a one-for-twenty-five (25) reverse stock split (the \u201cReverse Stock Split\u201d) of the Common Stock, and on March 18, 2025, the Company filed the Ninth Amendment with the Secretary of State of the State of Delaw ||| [0000950170-25-040784 8-K 2025-03-18]  State of the State of Delaware. The Reverse Stock Split will become effective in accordance with the terms of the Eighth Amendment at 12:01 am Eastern Time on March 24, 2025 (the \u201cEffective Time\u201d). When the Reverse Stock Split becomes effective, every twenty-five (25) shares of the Company\u2019s issued and outstanding Common Stock imme ||| [0001193125-26-179391 8-K 2026-04-27]  Company\u2019s board of directors (the \u201cBoard\u201d) on or before April 20, 2027. Pursuant to such authority granted by the Company\u2019s stockholders, the Board approved a one-for-thirty-five (35) reverse stock split (the \u201cReverse Stock Split\u201d) of the Common Stock, and on April 24, 2026, the Company filed the Eleventh Amendment with the Secretary of State of the State of De ||| [0001193125-26-179391 8-K 2026-04-27] tate of the State of Delaware. The Reverse Stock Split will become effective in accordance with the terms of the Eleventh Amendment at 12:01 am Eastern Time on April 30, 2026 (the \u201cEffective Time\u201d). When the Reverse Stock Split becomes effective, every thirty-five (35) shares of the Company\u2019s issued and outstanding Common Stock imme ||| [0001193125-26-391415 8-K 2026-09-15]  Company\u2019s board of directors (the \u201cBoard\u201d) on or before April 20, 2027. Pursuant to such authority granted by the Company\u2019s stockholders, the Board approved a one-for-fifteen (15) reverse stock split (the \u201cReverse Stock Split\u201d) of the Common Stock, and on September 14, 2026, the Company filed the Twelfth Amendment with the Secretary of State of the State of ||| [0001193125-26-391415 8-K 2026-09-15] State of the State of Delaware. The Reverse Stock Split will become effective in accordance with the terms of the Twelfth Amendment at 12:01 am Eastern Time on September 17, 2026 (the \u201cEffective Time\u201d). When the Reverse Stock Split becomes effective, every fifteen (15) shares of the Company\u2019s issued and outstanding Common Stock immediat",
   "supporting_passages": [
    "[0001104659-24-064484 8-K 2024-05-23] ompany\u2019s board of directors (the \u201cBoard\u201d) on or before January 22, 2025. Pursuant to such authority granted by the Company\u2019s stockholders, the Board approved a one-for-sixty (60) reverse stock split (the \u201cReverse Stock Split\u201d) of the Common Stock , and on May 17, 2024, the Company filed the Eighth Amendment with the Secretary of State of the State of Delaw",
    "[0001104659-24-064484 8-K 2024-05-23]  exchange on which registered Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital Market Item 1.01 Entry into a Material Definitive Agreement. On May 23, 2024, Jaguar Health, Inc. (the \u201cCompany\u201d) entered into an amendment (the \u201cSecond ATM Amendment\u201d) to that certain At the Market Offering Agreement, dated December 10",
    "[0000950170-25-040784 8-K 2025-03-18]  Company\u2019s board of directors (the \u201cBoard\u201d) on or before March 13, 2026. Pursuant to such authority granted by the Company\u2019s stockholders, the Board approved a one-for-twenty-five (25) reverse stock split (the \u201cReverse Stock Split\u201d) of the Common Stock, and on March 18, 2025, the Company filed the Ninth Amendment with the Secretary of State of the State of Delaw",
    "[0000950170-25-040784 8-K 2025-03-18]  State of the State of Delaware. The Reverse Stock Split will become effective in accordance with the terms of the Eighth Amendment at 12:01 am Eastern Time on March 24, 2025 (the \u201cEffective Time\u201d). When the Reverse Stock Split becomes effective, every twenty-five (25) shares of the Company\u2019s issued and outstanding Common Stock imme",
    "[0001193125-26-179391 8-K 2026-04-27]  Company\u2019s board of directors (the \u201cBoard\u201d) on or before April 20, 2027. Pursuant to such authority granted by the Company\u2019s stockholders, the Board approved a one-for-thirty-five (35) reverse stock split (the \u201cReverse Stock Split\u201d) of the Common Stock, and on April 24, 2026, the Company filed the Eleventh Amendment with the Secretary of State of the State of De",
    "[0001193125-26-179391 8-K 2026-04-27] tate of the State of Delaware. The Reverse Stock Split will become effective in accordance with the terms of the Eleventh Amendment at 12:01 am Eastern Time on April 30, 2026 (the \u201cEffective Time\u201d). When the Reverse Stock Split becomes effective, every thirty-five (35) shares of the Company\u2019s issued and outstanding Common Stock imme",
    "[0001193125-26-391415 8-K 2026-09-15]  Company\u2019s board of directors (the \u201cBoard\u201d) on or before April 20, 2027. Pursuant to such authority granted by the Company\u2019s stockholders, the Board approved a one-for-fifteen (15) reverse stock split (the \u201cReverse Stock Split\u201d) of the Common Stock, and on September 14, 2026, the Company filed the Twelfth Amendment with the Secretary of State of the State of",
    "[0001193125-26-391415 8-K 2026-09-15] State of the State of Delaware. The Reverse Stock Split will become effective in accordance with the terms of the Twelfth Amendment at 12:01 am Eastern Time on September 17, 2026 (the \u201cEffective Time\u201d). When the Reverse Stock Split becomes effective, every fifteen (15) shares of the Company\u2019s issued and outstanding Common Stock immediat"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Each 8-K states an approved RANGE (e.g. 1-for-15 to 1-for-150) before the chosen ratio; a tool that reports the range bound instead of the board-chosen ratio is wrong. Jaguar filed many other Item 5.03 8-Ks in the window (preferred-stock designations) that are not splits; the January 2023 1-for-75 split is outside the window.",
   "difficulty_features": [
    "multi-filing (4 filings)",
    "ratio vs authorised range",
    "arithmetic"
   ],
   "question": "Between January 1, 2024 and October 31, 2026, how many reverse stock splits did Jaguar Health (JAGX) effect, at what ratios, and what is the cumulative reverse-split factor across them?"
  },
  {
   "id": "R3-08",
   "ticker": "SEGG",
   "category": "cash",
   "answer": "$785,905 at March 31, 2026 (Q1 2026 Form 10-Q, filed October 8, 2026). The Q2 2026 10-Q was not filed until November 2, 2026.",
   "accepted_variants": [
    "$785,905",
    "785,905"
   ],
   "as_of": "March 31, 2026 balance; reports filed on or before October 31, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-046279",
     "form": "10-Q",
     "filing_date": "2026-10-08",
     "url": "https://www.sec.gov/Archives/edgar/data/1673481/000149315226046279/form10-q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1673481/000149315226046279/",
     "role": "Q1 2026 10-Q"
    }
   ],
   "supporting_passage": "[0001493152-26-046279 10-Q 2026-10-08] ited) F-5 1 SPORTS ENTERTAINMENT GAMING GLOBAL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2026 December 31, 2025 ASSETS Current assets: Cash $ 785,905 $ 171,524 Restricted Cash - - Accounts receivable, net 1,288,309 231,259 Inventory 260,653 - Prepaid expenses 8,958,148 8,634,275 Other current assets 3,237,23",
   "supporting_passages": [
    "[0001493152-26-046279 10-Q 2026-10-08] ited) F-5 1 SPORTS ENTERTAINMENT GAMING GLOBAL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2026 December 31, 2025 ASSETS Current assets: Cash $ 785,905 $ 171,524 Restricted Cash - - Accounts receivable, net 1,288,309 231,259 Inventory 260,653 - Prepaid expenses 8,958,148 8,634,275 Other current assets 3,237,23"
   ],
   "xbrl_facts": [
    {
     "tag": "CashAndCashEquivalentsAtCarryingValue",
     "value": 785905,
     "period_start": null,
     "period_end": "2026-03-31",
     "accession": "0001493152-26-046279"
    },
    {
     "tag": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "value": 785905,
     "period_start": null,
     "period_end": "2026-03-31",
     "accession": "0001493152-26-046279"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Delinquent filer: the June 30, 2026 10-Q arrived November 2, 2026, after the as-of date. The December 31, 2025 figure ($171,524, FY2025 10-K and 10-K/A) is also stale.",
   "difficulty_features": [
    "as-of discipline (late filer)"
   ],
   "question": "Using only reports Sports Entertainment Gaming Global (SEGG) had filed with the SEC on or before October 31, 2026: what was its most recently reported quarter-end cash and cash equivalents, and for which balance-sheet date?"
  },
  {
   "id": "R3-09",
   "ticker": "SURG",
   "category": "shares_float",
   "answer": "Cover: 52,908,423 shares outstanding as of August 19, 2026. Balance sheet: 26,511,665 shares at June 30, 2026 (10-Q for the quarter ended June 30, 2026).",
   "accepted_variants": [
    "52,908,423",
    "26,511,665"
   ],
   "as_of": "Cover date August 19, 2026; balance sheet June 30, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-039250",
     "form": "10-Q",
     "filing_date": "2026-08-19",
     "url": "https://www.sec.gov/Archives/edgar/data/1392694/000149315226039250/form10-q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1392694/000149315226039250/",
     "role": "Q2 2026 10-Q"
    }
   ],
   "supporting_passage": "[0001493152-26-039250 10-Q 2026-08-19]  company (as defined in rule 12b-2 of the Exchange Act). Yes \u2610 No \u2612 The number of shares of the registrant\u2019s common stock outstanding as of August 19, 2026 was 52,908,423 shares. SurgePays, Inc. and Subsidiaries Page(s) Consolidated Balance Sheets (Unaudited) 3 Consolidated Statements of Operations (Unaudited) 4 Consolidated Sta ||| [0001493152-26-039250 10-Q 2026-08-19] bilities 29,987,865 23,918,665 Stockholders\u2019 Deficit Common stock, $ 0.001 par value, 500,000,000 shares authorized 27,207,618 and 21,847,927 shares issued and 26,511,665 and 21,151,974 shares outstanding, at June 30, 2026 and December 31, 2025, respectively 27,211 21,852 Additional paid-in capital 88,657,683 83,246,736 Treasury",
   "supporting_passages": [
    "[0001493152-26-039250 10-Q 2026-08-19]  company (as defined in rule 12b-2 of the Exchange Act). Yes \u2610 No \u2612 The number of shares of the registrant\u2019s common stock outstanding as of August 19, 2026 was 52,908,423 shares. SurgePays, Inc. and Subsidiaries Page(s) Consolidated Balance Sheets (Unaudited) 3 Consolidated Statements of Operations (Unaudited) 4 Consolidated Sta",
    "[0001493152-26-039250 10-Q 2026-08-19] bilities 29,987,865 23,918,665 Stockholders\u2019 Deficit Common stock, $ 0.001 par value, 500,000,000 shares authorized 27,207,618 and 21,847,927 shares issued and 26,511,665 and 21,151,974 shares outstanding, at June 30, 2026 and December 31, 2025, respectively 27,211 21,852 Additional paid-in capital 88,657,683 83,246,736 Treasury"
   ],
   "xbrl_facts": [
    {
     "tag": "EntityCommonStockSharesOutstanding",
     "value": 52908423,
     "period_start": null,
     "period_end": "2026-08-19",
     "accession": "0001493152-26-039250"
    },
    {
     "tag": "CommonStockSharesOutstanding",
     "value": 26511665,
     "period_start": null,
     "period_end": "2026-06-30",
     "accession": "0001493152-26-039250"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "The two counts differ by 2.0x because of post-quarter issuance; a tool that reports only one, or treats the cover count as the quarter-end count, misses half the answer. A later Q3 10-Q filed after October 31, 2026 must not be used.",
   "difficulty_features": [
    "cover vs balance sheet",
    "as-of discipline"
   ],
   "question": "In the most recent Form 10-Q that SurgePays (SURG) had filed on or before October 31, 2026, how many shares of common stock were outstanding as of the cover-page date, and how many were issued and outstanding on the balance sheet at the end of the quarter?"
  },
  {
   "id": "R3-10",
   "ticker": "BFRG",
   "category": "other_8k",
   "answer": "February 8, 2027 (second 180-calendar-day compliance period granted August 18, 2026; the initial period ran to August 10, 2026).",
   "accepted_variants": [
    "February 8, 2027"
   ],
   "as_of": "October 31, 2026",
   "primary_source": [
    {
     "accession": "0001628280-26-058143",
     "form": "8-K",
     "filing_date": "2026-08-20",
     "url": "https://www.sec.gov/Archives/edgar/data/1829247/000162828026058143/bfrg-20260818.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1829247/000162828026058143/",
     "role": "extension 8-K"
    }
   ],
   "supporting_passage": "[0001628280-26-058143 8-K 2026-08-20] regained compliance with the Minimum Bid Price Requirement, the Staff had determined that the Company is eligible for an additional 180 calendar day period, or until February 8, 2027 (the \u201cSecond Compliance Period\u201d), to regain compliance. In connection with the grant of the Second Compliance Period, the Company provided notice to Nasdaq tha ||| [0001628280-26-058143 8-K 2026-08-20]  (the \u201cBid Price Notice\u201d). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial compliance period of 180 calendar days, or until August 10, 2026, to regain compliance with the Minimum Bid Price Requirement. On August 18, 2026 , Nasdaq notified the Company that, while the Company has not yet regained com",
   "supporting_passages": [
    "[0001628280-26-058143 8-K 2026-08-20] regained compliance with the Minimum Bid Price Requirement, the Staff had determined that the Company is eligible for an additional 180 calendar day period, or until February 8, 2027 (the \u201cSecond Compliance Period\u201d), to regain compliance. In connection with the grant of the Second Compliance Period, the Company provided notice to Nasdaq tha",
    "[0001628280-26-058143 8-K 2026-08-20]  (the \u201cBid Price Notice\u201d). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial compliance period of 180 calendar days, or until August 10, 2026, to regain compliance with the Minimum Bid Price Requirement. On August 18, 2026 , Nasdaq notified the Company that, while the Company has not yet regained com"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "The initial deficiency notice gave a deadline of August 10, 2026, which is superseded; no later 8-K through October 31, 2026 reports compliance or delisting.",
   "difficulty_features": [
    "superseded deadline",
    "find latest filing"
   ],
   "question": "As of October 31, 2026, by what date did Bullfrog AI Holdings (BFRG) have to regain compliance with Nasdaq's $1.00 minimum bid price requirement?"
  },
  {
   "id": "R3-11",
   "ticker": "ECOR",
   "category": "dilution",
   "answer": "$15.7 million under the Sales Agreement (originally up to $20.0 million, entered November 29, 2024), within $95.9 million remaining under the 2025 shelf registration statement (File No. 333-284477).",
   "accepted_variants": [
    "$15.7 million",
    "$95.9 million"
   ],
   "as_of": "September 30, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-049961",
     "form": "10-Q",
     "filing_date": "2026-11-04",
     "url": "https://www.sec.gov/Archives/edgar/data/1560258/000149315226049961/form10-q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1560258/000149315226049961/",
     "role": "Q3 2026 10-Q"
    }
   ],
   "supporting_passage": "[0001493152-26-049961 10-Q 2026-11-04] to time by us in connection with the issuance by us of the securities registered under the 2025 Shelf Registration Statement. As of September 30, 2026, we have $ 95.9 million remaining for potential issuance under the 2025 Shelf Registration Statement (including $ 15.7 million under the Sales Agreement (as defined below)). If we raise additional funds by issuing equity or debt securities, either through the sale of securities pursuant to a registration statem ||| [0001493152-26-049961 10-Q 2026-11-04] Wainwright & Co., LLC (\u201cWainwright\u201d), whereby the Company may offer and sell shares of its common stock from time to time having an aggregate offering price of up to $ 20.0 million by any method deemed to be an \u201cat-the-market\u201d offering (\u201cATM\u201d) as defined in Rule 415 of the Securities Act, or any other method specified in the Sales Agreeme",
   "supporting_passages": [
    "[0001493152-26-049961 10-Q 2026-11-04] to time by us in connection with the issuance by us of the securities registered under the 2025 Shelf Registration Statement. As of September 30, 2026, we have $ 95.9 million remaining for potential issuance under the 2025 Shelf Registration Statement (including $ 15.7 million under the Sales Agreement (as defined below)). If we raise additional funds by issuing equity or debt securities, either through the sale of securities pursuant to a registration statem",
    "[0001493152-26-049961 10-Q 2026-11-04] Wainwright & Co., LLC (\u201cWainwright\u201d), whereby the Company may offer and sell shares of its common stock from time to time having an aggregate offering price of up to $ 20.0 million by any method deemed to be an \u201cat-the-market\u201d offering (\u201cATM\u201d) as defined in Rule 415 of the Securities Act, or any other method specified in the Sales Agreeme"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "The ATM capacity is a sub-limit inside the shelf: adding $15.7m + $95.9m double-counts, and quoting the $20.0 million original cap ignores sales already made.",
   "difficulty_features": [
    "nested limits (ATM within shelf)",
    "footnote reading"
   ],
   "question": "As of September 30, 2026, how much remained available under electroCore's (ECOR) at-the-market sales agreement with H.C. Wainwright, and how much remained for potential issuance under its 2025 shelf registration overall?"
  },
  {
   "id": "R3-12",
   "ticker": "IVF",
   "category": "reverse_split",
   "answer": "Four: 1-for-12 (effective March 18, 2025), 1-for-3 (July 21, 2025), 1-for-8 (November 28, 2025) and 1-for-5 (March 27, 2026). Cumulative factor 12 x 3 x 8 x 5 = 1,440.",
   "accepted_variants": [
    "4 reverse splits",
    "1,440",
    "1-for-1,440"
   ],
   "as_of": "Window January 1, 2025 to October 15, 2026",
   "primary_source": [
    {
     "accession": "0001641172-25-000316",
     "form": "8-K",
     "filing_date": "2025-03-24",
     "url": "https://www.sec.gov/Archives/edgar/data/1417926/000164117225000316/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1417926/000164117225000316/",
     "role": "split 1"
    },
    {
     "accession": "0001641172-25-020406",
     "form": "8-K",
     "filing_date": "2025-07-21",
     "url": "https://www.sec.gov/Archives/edgar/data/1417926/000164117225020406/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1417926/000164117225020406/",
     "role": "split 2"
    },
    {
     "accession": "0001493152-25-025977",
     "form": "8-K",
     "filing_date": "2025-12-03",
     "url": "https://www.sec.gov/Archives/edgar/data/1417926/000149315225025977/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1417926/000149315225025977/",
     "role": "split 3"
    },
    {
     "accession": "0001493152-26-014227",
     "form": "8-K",
     "filing_date": "2026-03-31",
     "url": "https://www.sec.gov/Archives/edgar/data/1417926/000149315226014227/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1417926/000149315226014227/",
     "role": "split 4"
    },
    {
     "accession": "0001493152-26-049991",
     "form": "8-K",
     "filing_date": "2026-11-04",
     "url": "https://www.sec.gov/Archives/edgar/data/1417926/000149315226049991/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1417926/000149315226049991/",
     "role": "trap: outside window"
    }
   ],
   "supporting_passage": "[0001641172-25-000316 8-K 2025-03-24] th, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture (\u201cIVC\u201d) fertility treatments, announced today that it will effect a 1-for-12 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on March 18, 2025. Commencing with the opening  ||| [0001641172-25-000316 8-K 2025-03-24] EX-3.1 2 ex3-1.htm Exhibit 3.1  [[DOC ex99-1.htm]]  EX-99.1 3 ex99-1.htm Exhibit 99.1 NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025 SARASOTA, Fla. and MIAMI, Mar. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. (\u201cNAYA\u201d) (NASDAQ: NAYA), a life science portfolio company dedicated to bring ||| [0001641172-25-020406 8-K 2025-07-21] 025 (GLOBE NEWSWIRE) \u2013 INVO Fertility, Inc. (\u201cINVO\u201d) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-3 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on July 21, 2025. Commencing with the opening o ||| [0001641172-25-020406 8-K 2025-07-21] 1 Exhibit 3.1  [[DOC ex99-1.htm]]  EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 INVO Fertility Announces a 1:3 Reverse Stock Split Effective Pre-Market Opening on July 21, 2025 SARASOTA, Fla., July 17, 2025 (GLOBE NEWSWIRE) \u2013 INVO Fertility, Inc. (\u201cINVO\u201d) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced t ||| [0001493152-25-025977 8-K 2025-12-03] 025 (GLOBE NEWSWIRE) \u2013 INVO Fertility, Inc. (\u201cINVO\u201d) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-8 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on November 28, 2025. Commencing with the openi ||| [0001493152-25-025977 8-K 2025-12-03] 1 Exhibit 3.1  [[DOC ex99-1.htm]]  EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 INVO Fertility Announces a 1:8 Reverse Stock Split Effective Pre-Market Opening on November 28, 2025 SARASOTA, Fla., November 25, 2025 (GLOBE NEWSWIRE) \u2013 INVO Fertility, Inc. (\u201cINVO\u201d) (NASDAQ: IVF), a healthcare company focused on the fertility market, announc ||| [0001493152-26-014227 8-K 2026-03-31] 026 (GLOBE NEWSWIRE) \u2013 INVO Fertility, Inc. (\u201cINVO\u201d) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-5 reverse split of its issued and outstanding and of its authorized common stock effective as of 12:01 a.m. Eastern Time on March 27, 2026. Commencing with the o ||| [0001493152-26-014227 8-K 2026-03-31] 1 Exhibit 3.1  [[DOC ex99-1.htm]]  EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 INVO Fertility Announces a 1:5 Reverse Stock Split Effective Pre-Market Opening on March 27, 2026 SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) \u2013 INVO Fertility, Inc. (\u201cINVO\u201d) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced  ||| [0001493152-26-049991 8-K 2026-11-04]  has filed a Certificate of Change (the \u201cCertificate of Change\u201d) with the Secretary of State of the State of Nevada, effective October 30, 2026 to effectuate a 1-for-4 reverse stock split (the \u201cReverse Stock Split\u201d) of the Company\u2019s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (\u201cCommon Stock\u201d). The Re ||| [0001493152-26-049991 8-K 2026-11-04]  Year. INVO Fertility, Inc. (the \u201cCompany\u201d) has filed a Certificate of Change (the \u201cCertificate of Change\u201d) with the Secretary of State of the State of Nevada, effective October 30, 2026 to effectuate a 1-for-4 reverse stock split (the \u201cReverse Stock Split\u201d) of the Company\u2019s issued and outstanding and authorized shares of common stock, par valu",
   "supporting_passages": [
    "[0001641172-25-000316 8-K 2025-03-24] th, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture (\u201cIVC\u201d) fertility treatments, announced today that it will effect a 1-for-12 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on March 18, 2025. Commencing with the opening ",
    "[0001641172-25-000316 8-K 2025-03-24] EX-3.1 2 ex3-1.htm Exhibit 3.1  [[DOC ex99-1.htm]]  EX-99.1 3 ex99-1.htm Exhibit 99.1 NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025 SARASOTA, Fla. and MIAMI, Mar. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. (\u201cNAYA\u201d) (NASDAQ: NAYA), a life science portfolio company dedicated to bring",
    "[0001641172-25-020406 8-K 2025-07-21] 025 (GLOBE NEWSWIRE) \u2013 INVO Fertility, Inc. (\u201cINVO\u201d) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-3 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on July 21, 2025. Commencing with the opening o",
    "[0001641172-25-020406 8-K 2025-07-21] 1 Exhibit 3.1  [[DOC ex99-1.htm]]  EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 INVO Fertility Announces a 1:3 Reverse Stock Split Effective Pre-Market Opening on July 21, 2025 SARASOTA, Fla., July 17, 2025 (GLOBE NEWSWIRE) \u2013 INVO Fertility, Inc. (\u201cINVO\u201d) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced t",
    "[0001493152-25-025977 8-K 2025-12-03] 025 (GLOBE NEWSWIRE) \u2013 INVO Fertility, Inc. (\u201cINVO\u201d) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-8 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on November 28, 2025. Commencing with the openi",
    "[0001493152-25-025977 8-K 2025-12-03] 1 Exhibit 3.1  [[DOC ex99-1.htm]]  EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 INVO Fertility Announces a 1:8 Reverse Stock Split Effective Pre-Market Opening on November 28, 2025 SARASOTA, Fla., November 25, 2025 (GLOBE NEWSWIRE) \u2013 INVO Fertility, Inc. (\u201cINVO\u201d) (NASDAQ: IVF), a healthcare company focused on the fertility market, announc",
    "[0001493152-26-014227 8-K 2026-03-31] 026 (GLOBE NEWSWIRE) \u2013 INVO Fertility, Inc. (\u201cINVO\u201d) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-5 reverse split of its issued and outstanding and of its authorized common stock effective as of 12:01 a.m. Eastern Time on March 27, 2026. Commencing with the o",
    "[0001493152-26-014227 8-K 2026-03-31] 1 Exhibit 3.1  [[DOC ex99-1.htm]]  EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 INVO Fertility Announces a 1:5 Reverse Stock Split Effective Pre-Market Opening on March 27, 2026 SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) \u2013 INVO Fertility, Inc. (\u201cINVO\u201d) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced ",
    "[0001493152-26-049991 8-K 2026-11-04]  has filed a Certificate of Change (the \u201cCertificate of Change\u201d) with the Secretary of State of the State of Nevada, effective October 30, 2026 to effectuate a 1-for-4 reverse stock split (the \u201cReverse Stock Split\u201d) of the Company\u2019s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (\u201cCommon Stock\u201d). The Re",
    "[0001493152-26-049991 8-K 2026-11-04]  Year. INVO Fertility, Inc. (the \u201cCompany\u201d) has filed a Certificate of Change (the \u201cCertificate of Change\u201d) with the Secretary of State of the State of Nevada, effective October 30, 2026 to effectuate a 1-for-4 reverse stock split (the \u201cReverse Stock Split\u201d) of the Company\u2019s issued and outstanding and authorized shares of common stock, par valu"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "A fifth split (1-for-4, effective October 30, 2026, 8-K filed November 4, 2026) falls after the window; including it gives 5,760. The July 24, 2026 Item 5.03 8-K is not a split.",
   "difficulty_features": [
    "multi-filing (4 filings)",
    "date-window exclusion",
    "arithmetic"
   ],
   "question": "Between January 1, 2025 and October 15, 2026, how many reverse stock splits did INVO Fertility (IVF) make effective, and what is the cumulative reverse-split factor?"
  },
  {
   "id": "R3-13",
   "ticker": "CELU",
   "category": "cash",
   "answer": "$368 thousand at March 31, 2026 (Q1 2026 Form 10-Q filed September 29, 2026). Cash, cash equivalents and restricted cash totalled $10.477 million, of which $10.109 million was non-current restricted cash.",
   "accepted_variants": [
    "$368,000",
    "$0.4 million",
    "368 thousand",
    "$368"
   ],
   "as_of": "March 31, 2026 balance; reports filed on or before October 15, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-044892",
     "form": "10-Q",
     "filing_date": "2026-09-29",
     "url": "https://www.sec.gov/Archives/edgar/data/1752828/000149315226044892/form10-q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1752828/000149315226044892/",
     "role": "Q1 2026 10-Q"
    }
   ],
   "supporting_passage": "[0001493152-26-044892 10-Q 2026-09-29] Inc. Unaudited Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) March 31, December 31, 2026 2025 Assets Current assets: Cash and cash equivalents $ 368 $ 6,175 Accounts receivable, net of allowance of $ 7,847 and $ 7,647 as of March 31, 2026 and December 31, 2025, respectively 4,781 4,653 Inventory 477 571 Prepaid exp ||| [0001493152-26-044892 10-Q 2026-09-29] ts 6,301 12,319 Property and equipment, net 54,568 55,797 Goodwill 7,347 7,347 Intangible assets, net 7,388 7,756 Right-of-use assets - operating 10,701 10,720 Restricted cash 10,109 10,197 Inventory, net of current portion 2,825 2,946 Other long-term assets 241 247 Total assets $ 99,480 $ 107,329 Liabilities and Stockholders\u2019 Deficit Curre ||| [0001493152-26-044892 10-Q 2026-09-29] sh equivalents and restricted cash ( 5,895 ) ( 673 ) Cash, cash equivalents and restricted cash at beginning of period 16,372 10,977 Cash, cash equivalents and restricted cash at end of period $ 10,477 $ 10,304 Supplemental non-cash investing and financing activities: Contingent consideration accrued in connection with Rebound asset acquisition - $ 650 Deemed",
   "supporting_passages": [
    "[0001493152-26-044892 10-Q 2026-09-29] Inc. Unaudited Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) March 31, December 31, 2026 2025 Assets Current assets: Cash and cash equivalents $ 368 $ 6,175 Accounts receivable, net of allowance of $ 7,847 and $ 7,647 as of March 31, 2026 and December 31, 2025, respectively 4,781 4,653 Inventory 477 571 Prepaid exp",
    "[0001493152-26-044892 10-Q 2026-09-29] ts 6,301 12,319 Property and equipment, net 54,568 55,797 Goodwill 7,347 7,347 Intangible assets, net 7,388 7,756 Right-of-use assets - operating 10,701 10,720 Restricted cash 10,109 10,197 Inventory, net of current portion 2,825 2,946 Other long-term assets 241 247 Total assets $ 99,480 $ 107,329 Liabilities and Stockholders\u2019 Deficit Curre",
    "[0001493152-26-044892 10-Q 2026-09-29] sh equivalents and restricted cash ( 5,895 ) ( 673 ) Cash, cash equivalents and restricted cash at beginning of period 16,372 10,977 Cash, cash equivalents and restricted cash at end of period $ 10,477 $ 10,304 Supplemental non-cash investing and financing activities: Contingent consideration accrued in connection with Rebound asset acquisition - $ 650 Deemed"
   ],
   "xbrl_facts": [
    {
     "tag": "CashAndCashEquivalentsAtCarryingValue",
     "value": 368000,
     "period_start": null,
     "period_end": "2026-03-31",
     "accession": "0001493152-26-044892"
    },
    {
     "tag": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "value": 10477000,
     "period_start": null,
     "period_end": "2026-03-31",
     "accession": "0001493152-26-044892"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Two traps: (1) as-of: the Q2 10-Q was filed October 20, 2026; (2) the cash-flow statement total of $10,477 thousand includes $10,109 thousand of non-current restricted cash, so quoting ~$10.5 million is wrong for the balance-sheet line.",
   "difficulty_features": [
    "as-of discipline (late filer)",
    "restricted cash vs cash"
   ],
   "question": "Using only reports Celularity (CELU) had filed on or before October 15, 2026: what were its most recently reported quarter-end cash and cash equivalents on the balance sheet (excluding restricted cash), and the balance-sheet date?"
  },
  {
   "id": "R3-14",
   "ticker": "MITI",
   "category": "shares_float",
   "answer": "Cover: 48,392,796 shares outstanding as of August 17, 2026. Balance sheet: 20,940,597 shares at June 30, 2026 (10-Q for the quarter ended June 30, 2026).",
   "accepted_variants": [
    "48,392,796",
    "20,940,597"
   ],
   "as_of": "Cover date August 17, 2026; balance sheet June 30, 2026",
   "primary_source": [
    {
     "accession": "0001185185-26-003575",
     "form": "10-Q",
     "filing_date": "2026-08-17",
     "url": "https://www.sec.gov/Archives/edgar/data/802257/000118518526003575/miti10q063026.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/802257/000118518526003575/",
     "role": "Q2 2026 10-Q"
    }
   ],
   "supporting_passage": "[0001185185-26-003575 10-Q 2026-08-17] cate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes \u2610 No \u2612 As of August 17, 2026 the registrant had 48,392,796 shares of common stock issued and outstanding. Table of Contents Page PART I \u2013 FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited) Consolidated Bala ||| [0001185185-26-003575 10-Q 2026-08-17] 03 shares issued and outstanding as of June 30, 2026, and December 31, 205, respectively 517 421 Common stock, $ 0.01 par value, 500,000,000 shares authorized, 20,940,597 and 15,093,055 shares issued and outstanding as of June 30, 2026, and December 31, 2025, respectively 209,405 150,931 Additional paid-in capital 40,587,568 39,",
   "supporting_passages": [
    "[0001185185-26-003575 10-Q 2026-08-17] cate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes \u2610 No \u2612 As of August 17, 2026 the registrant had 48,392,796 shares of common stock issued and outstanding. Table of Contents Page PART I \u2013 FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited) Consolidated Bala",
    "[0001185185-26-003575 10-Q 2026-08-17] 03 shares issued and outstanding as of June 30, 2026, and December 31, 205, respectively 517 421 Common stock, $ 0.01 par value, 500,000,000 shares authorized, 20,940,597 and 15,093,055 shares issued and outstanding as of June 30, 2026, and December 31, 2025, respectively 209,405 150,931 Additional paid-in capital 40,587,568 39,"
   ],
   "xbrl_facts": [
    {
     "tag": "EntityCommonStockSharesOutstanding",
     "value": 48392796,
     "period_start": null,
     "period_end": "2026-08-17",
     "accession": "0001185185-26-003575"
    },
    {
     "tag": "CommonStockSharesIssued",
     "value": 20940597,
     "period_start": null,
     "period_end": "2026-06-30",
     "accession": "0001185185-26-003575"
    },
    {
     "tag": "CommonStockSharesOutstanding",
     "value": 20940597,
     "period_start": null,
     "period_end": "2026-06-30",
     "accession": "0001185185-26-003575"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "The two counts differ by 2.3x because of post-quarter issuance; a tool that reports only one, or treats the cover count as the quarter-end count, misses half the answer. A later Q3 10-Q filed after October 31, 2026 must not be used.",
   "difficulty_features": [
    "cover vs balance sheet",
    "as-of discipline"
   ],
   "question": "In the most recent Form 10-Q that Mitesco (MITI) had filed on or before October 31, 2026, how many shares of common stock were outstanding as of the cover-page date, and how many were issued and outstanding on the balance sheet at the end of the quarter?"
  },
  {
   "id": "R3-15",
   "ticker": "NUAI",
   "category": "other_amended",
   "answer": "$10,823,974 (as restated in the Form 10-Q/A filed August 14, 2026); originally reported as $8,991,887. Net loss per share $(0.19) restated vs $(0.16).",
   "accepted_variants": [
    "$10,823,974",
    "$10.8 million"
   ],
   "as_of": "Quarter ended March 31, 2026; amendments through October 31, 2026",
   "primary_source": [
    {
     "accession": "0001213900-26-090122",
     "form": "10-Q/A",
     "filing_date": "2026-08-14",
     "url": "https://www.sec.gov/Archives/edgar/data/2028336/000121390026090122/ea0301611-10qa1_newera.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/2028336/000121390026090122/",
     "role": "10-Q/A"
    },
    {
     "accession": "0001213900-26-057022",
     "form": "10-Q",
     "filing_date": "2026-05-15",
     "url": "https://www.sec.gov/Archives/edgar/data/2028336/000121390026057022/ea0289727-10q_newera.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/2028336/000121390026057022/",
     "role": "trap: original 10-Q"
    }
   ],
   "supporting_passage": "[0001213900-26-090122 10-Q/A 2026-08-14] ors described above, in addition to certain other immaterial errors, was an understatement of net loss of $1,832,087 for the three months ended March 31, 2026; as restated, net loss is $10,823,974 and net loss per share, basic and diluted, is $(0.19), as compared to $8,991,887 and $(0.16), respectively, as previously reported. The errors affected net los ||| [0001213900-26-090122 10-Q/A 2026-08-14] 1,832,087 for the three months ended March 31, 2026; as restated, net loss is $10,823,974 and net loss per share, basic and diluted, is $(0.19), as compared to $8,991,887 and $(0.16), respectively, as previously reported. The errors affected net loss, net loss per share, total assets, total liabilities and total stockholder\u2019s eq ||| [0001213900-26-057022 10-Q 2026-05-15]  - ( 15,403 ) Change in fair value of derivative liability 312,694 190,977 Total other income (expenses) ( 1,383,940 ) ( 1,251,168 ) Loss before income taxes ( 8,991,887 ) ( 3,320,256 ) Income tax provision - - Net loss ( 8,991,887 ) ( 3,320,256 ) Net loss per share - basic and diluted $ ( 0.16 ) $ ( 0.24 ) Weighted average num",
   "supporting_passages": [
    "[0001213900-26-090122 10-Q/A 2026-08-14] ors described above, in addition to certain other immaterial errors, was an understatement of net loss of $1,832,087 for the three months ended March 31, 2026; as restated, net loss is $10,823,974 and net loss per share, basic and diluted, is $(0.19), as compared to $8,991,887 and $(0.16), respectively, as previously reported. The errors affected net los",
    "[0001213900-26-090122 10-Q/A 2026-08-14] 1,832,087 for the three months ended March 31, 2026; as restated, net loss is $10,823,974 and net loss per share, basic and diluted, is $(0.19), as compared to $8,991,887 and $(0.16), respectively, as previously reported. The errors affected net loss, net loss per share, total assets, total liabilities and total stockholder\u2019s eq",
    "[0001213900-26-057022 10-Q 2026-05-15]  - ( 15,403 ) Change in fair value of derivative liability 312,694 190,977 Total other income (expenses) ( 1,383,940 ) ( 1,251,168 ) Loss before income taxes ( 8,991,887 ) ( 3,320,256 ) Income tax provision - - Net loss ( 8,991,887 ) ( 3,320,256 ) Net loss per share - basic and diluted $ ( 0.16 ) $ ( 0.24 ) Weighted average num"
   ],
   "xbrl_facts": [
    {
     "tag": "NetIncomeLoss",
     "value": -10823974,
     "period_start": "2026-01-01",
     "period_end": "2026-03-31",
     "accession": "0001213900-26-090122"
    },
    {
     "tag": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "value": -10823974,
     "period_start": "2026-01-01",
     "period_end": "2026-03-31",
     "accession": "0001213900-26-090122"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "The original Q1 10-Q (May 15, 2026) shows $8,991,887; the 10-Q/A restates it by $1,832,087. A tool citing the original filing is stale.",
   "difficulty_features": [
    "amended filing supersedes original"
   ],
   "question": "What was New Era Energy & Digital's (NUAI) net loss for the three months ended March 31, 2026, as currently reported after any amendment filed on or before October 31, 2026?"
  },
  {
   "id": "R3-16",
   "ticker": "VTGN",
   "category": "dilution",
   "answer": "Up to $175 million in total; approximately $139.5 million remained available at June 30, 2026 (first quarter of fiscal 2027). 1,580,176 shares were sold under it in the quarter.",
   "accepted_variants": [
    "$139.5 million",
    "$175 million"
   ],
   "as_of": "June 30, 2026",
   "primary_source": [
    {
     "accession": "0001628280-26-057116",
     "form": "10-Q",
     "filing_date": "2026-08-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1411685/000162828026057116/vtgn-20260630.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1411685/000162828026057116/",
     "role": "10-Q for quarter ended June 30, 2026"
    }
   ],
   "supporting_passage": "[0001628280-26-057116 10-Q 2026-08-14] ng program under which the Company was permitted, at the Company's option, to offer and sell, from time to time, shares of the Company's common stock having an aggregate offering price of up to $ 175 million. As of June 30, 2026, shares of common stock with an aggregate offering price of approximately $ 139.5 million remained available for offer and sale under the  ||| [0001628280-26-057116 10-Q 2026-08-14] mpany's common stock having an aggregate offering price of up to $ 175 million. As of June 30, 2026, shares of common stock with an aggregate offering price of approximately $ 139.5 million remained available for offer and sale under the Sales Agreement. During the three months ended June 30, 2026, the Company sold 1,580,176 shares of the Company's common stock in a",
   "supporting_passages": [
    "[0001628280-26-057116 10-Q 2026-08-14] ng program under which the Company was permitted, at the Company's option, to offer and sell, from time to time, shares of the Company's common stock having an aggregate offering price of up to $ 175 million. As of June 30, 2026, shares of common stock with an aggregate offering price of approximately $ 139.5 million remained available for offer and sale under the ",
    "[0001628280-26-057116 10-Q 2026-08-14] mpany's common stock having an aggregate offering price of up to $ 175 million. As of June 30, 2026, shares of common stock with an aggregate offering price of approximately $ 139.5 million remained available for offer and sale under the Sales Agreement. During the three months ended June 30, 2026, the Company sold 1,580,176 shares of the Company's common stock in a"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Vistagen's fiscal year ends March 31, so June 30, 2026 is the first quarter of fiscal 2027 and the figure sits in a 10-Q filed in August, not in the June 2026 10-K; quoting the $175 million cap as available capacity ignores sales already made.",
   "difficulty_features": [
    "non-calendar fiscal year",
    "cap vs remaining"
   ],
   "question": "As of June 30, 2026, what was the total size of Vistagen Therapeutics' (VTGN) at-the-market sales agreement and how much remained available under it?"
  },
  {
   "id": "R3-17",
   "ticker": "NVVE",
   "category": "reverse_split",
   "answer": "114,991 shares outstanding (114,993 issued) at December 31, 2025, after the 1-for-18 reverse split effective July 6, 2026.",
   "accepted_variants": [
    "114,991",
    "1-for-18",
    "July 6, 2026"
   ],
   "as_of": "December 31, 2025 balance, as restated in the 10-Q for the quarter ended March 31, 2026 (filed July 15, 2026)",
   "primary_source": [
    {
     "accession": "0001836875-26-000026",
     "form": "10-K",
     "filing_date": "2026-03-31",
     "url": "https://www.sec.gov/Archives/edgar/data/1836875/000183687526000026/nvve-20251231.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1836875/000183687526000026/",
     "role": "original figure"
    },
    {
     "accession": "0001836875-26-000059",
     "form": "10-Q",
     "filing_date": "2026-07-15",
     "url": "https://www.sec.gov/Archives/edgar/data/1836875/000183687526000059/nvve-20260331.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1836875/000183687526000059/",
     "role": "restated figure"
    },
    {
     "accession": "0001836875-26-000051",
     "form": "8-K",
     "filing_date": "2026-07-01",
     "url": "https://www.sec.gov/Archives/edgar/data/1836875/000183687526000051/nvve-20260630.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1836875/000183687526000051/",
     "role": "split 8-K"
    }
   ],
   "supporting_passage": "[0001836875-26-000026 10-K 2026-03-31] nding at December 31, 2025 and December 31, 2024, respectively \u2014 \u2014 Common stock, $ 0.0001 par value, 400,000,000 shares authorized; 2,069,882 shares issued and 2,069,840 shares outstanding at December 31, 2025; 22,624 shares issued and 22,582 shares outstanding at December 31, 2024. 11,758 6,408 Treasury stock, at cost, 42 shar ||| [0001836875-26-000059 10-Q 2026-07-15] 31, 2025, respectively \u2014 \u2014 Common stock, $ 0.0001 par value, 400,000,000 shares authorized; 348,567 shares issued and 348,565 outstanding at March 31, 2026 and 114,993 shares issued and 114,991 outstanding at December 31, 2025, respectively 12,178 11,758 Treasury stock, at cost, 2 shares outstanding at March 31, 2026 and December 31, 2025, respectively \u2014 \u2014 Additional paid-in ||| [0001836875-26-000059 10-Q 2026-07-15]  approved a proposal to authorize a reverse stock split of the Company\u2019s common stock, at a ratio within the range of 1-for-2 to 1-for-40. The Board approved a 1-for-18 reverse split ratio, which became effective July 6, 2026. Therefore, following the above Reverse Stock Split's effectiveness, all references in the condensed consolidated financial statements to number of common shar ||| [0001836875-26-000051 8-K 2026-07-01] ed and restated to read in its entirety as follows: \u201cC. Reverse Stock Split . Effective as of 12:01 a.m. Eastern Time on July 6, 2026 (the \u201c Effective Time \u201d), each eighteen (18) shares of Common Stock either issued and outstanding or held by the Corporation in treasury stock immediately prior to the Effective Time shall, automatically ",
   "supporting_passages": [
    "[0001836875-26-000026 10-K 2026-03-31] nding at December 31, 2025 and December 31, 2024, respectively \u2014 \u2014 Common stock, $ 0.0001 par value, 400,000,000 shares authorized; 2,069,882 shares issued and 2,069,840 shares outstanding at December 31, 2025; 22,624 shares issued and 22,582 shares outstanding at December 31, 2024. 11,758 6,408 Treasury stock, at cost, 42 shar",
    "[0001836875-26-000059 10-Q 2026-07-15] 31, 2025, respectively \u2014 \u2014 Common stock, $ 0.0001 par value, 400,000,000 shares authorized; 348,567 shares issued and 348,565 outstanding at March 31, 2026 and 114,993 shares issued and 114,991 outstanding at December 31, 2025, respectively 12,178 11,758 Treasury stock, at cost, 2 shares outstanding at March 31, 2026 and December 31, 2025, respectively \u2014 \u2014 Additional paid-in",
    "[0001836875-26-000059 10-Q 2026-07-15]  approved a proposal to authorize a reverse stock split of the Company\u2019s common stock, at a ratio within the range of 1-for-2 to 1-for-40. The Board approved a 1-for-18 reverse split ratio, which became effective July 6, 2026. Therefore, following the above Reverse Stock Split's effectiveness, all references in the condensed consolidated financial statements to number of common shar",
    "[0001836875-26-000051 8-K 2026-07-01] ed and restated to read in its entirety as follows: \u201cC. Reverse Stock Split . Effective as of 12:01 a.m. Eastern Time on July 6, 2026 (the \u201c Effective Time \u201d), each eighteen (18) shares of Common Stock either issued and outstanding or held by the Corporation in treasury stock immediately prior to the Effective Time shall, automatically "
   ],
   "xbrl_facts": [
    {
     "tag": "CommonStockSharesOutstanding",
     "value": 2069840,
     "period_start": null,
     "period_end": "2025-12-31",
     "accession": "0001836875-26-000026"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Simple division gives 114,991.1, but the filed figure distinguishes issued (114,993) from outstanding (114,991). The 1-for-18 ratio must be taken from the board's choice, not the approved 1-for-2 to 1-for-40 range. Nuvve also did a 1-for-40 split in January 2024, a 1-for-10 split in September 2024 and a 1-for-40 split in December 2025, all already reflected in the 10-K figure and must NOT be applied again.",
   "difficulty_features": [
    "split-adjusting an old figure",
    "issued vs outstanding",
    "avoid double-applying earlier splits"
   ],
   "question": "Nuvve Holding (NVVE) reported 2,069,840 shares of common stock outstanding at December 31, 2025 in its FY2025 Form 10-K. As retroactively restated in its later 2026 quarterly reports for the reverse split it effected in 2026, how many shares were outstanding at December 31, 2025, and what was the split ratio and effective date?"
  },
  {
   "id": "R3-18",
   "ticker": "XTIA",
   "category": "cash",
   "answer": "$15.185 million at March 31, 2026 (Q1 2026 Form 10-Q filed May 14, 2026). The Q2 2026 10-Q was not filed until October 20, 2026.",
   "accepted_variants": [
    "$15,185",
    "$15.2 million",
    "15,185,000"
   ],
   "as_of": "March 31, 2026 balance; reports filed on or before October 15, 2026",
   "primary_source": [
    {
     "accession": "0001213900-26-056270",
     "form": "10-Q",
     "filing_date": "2026-05-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1529113/000121390026056270/ea0289941-10q_xtiaero.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1529113/000121390026056270/",
     "role": "Q1 2026 10-Q"
    }
   ],
   "supporting_passage": "[0001213900-26-056270 10-Q 2026-05-14] IDATED BALANCE SHEETS (In thousands, except number of shares and par value data) As of March 31, 2026 As of December 31, 2025 (Unaudited) Assets Current Assets Cash and cash equivalents $ 15,185 $ 16,696 Accounts receivable, net 9,051 12,093 Inventories 19,413 15,400 Prepaid expenses and other current assets 6,688 3,989 Current assets of discontinued operations",
   "supporting_passages": [
    "[0001213900-26-056270 10-Q 2026-05-14] IDATED BALANCE SHEETS (In thousands, except number of shares and par value data) As of March 31, 2026 As of December 31, 2025 (Unaudited) Assets Current Assets Cash and cash equivalents $ 15,185 $ 16,696 Accounts receivable, net 9,051 12,093 Inventories 19,413 15,400 Prepaid expenses and other current assets 6,688 3,989 Current assets of discontinued operations"
   ],
   "xbrl_facts": [
    {
     "tag": "CashAndCashEquivalentsAtCarryingValue",
     "value": 15185000,
     "period_start": null,
     "period_end": "2026-03-31",
     "accession": "0001213900-26-056270"
    },
    {
     "tag": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "value": 15185000,
     "period_start": null,
     "period_end": "2026-03-31",
     "accession": "0001213900-26-056270"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "XTIA filed an NT 10-Q in August 2026 and its June 30, 2026 10-Q came on October 20, 2026, after the as-of date.",
   "difficulty_features": [
    "as-of discipline (late filer)"
   ],
   "question": "Using only reports XTI Aerospace (XTIA) had filed on or before October 15, 2026: what was its most recently reported quarter-end cash and cash equivalents, and for which date?"
  },
  {
   "id": "R3-19",
   "ticker": "YHC",
   "category": "shares_float",
   "answer": "Cover: 1,303,857 shares outstanding as of August 19, 2026. Balance sheet: 215,335 shares at June 30, 2026 (10-Q for the quarter ended June 30, 2026).",
   "accepted_variants": [
    "1,303,857",
    "215,335"
   ],
   "as_of": "Cover date August 19, 2026; balance sheet June 30, 2026",
   "primary_source": [
    {
     "accession": "0001213900-26-091661",
     "form": "10-Q",
     "filing_date": "2026-08-19",
     "url": "https://www.sec.gov/Archives/edgar/data/1843165/000121390026091661/ea0301268-10q_lqrhouse.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1843165/000121390026091661/",
     "role": "Q2 2026 10-Q"
    }
   ],
   "supporting_passage": "[0001213900-26-091661 10-Q 2026-08-19] s defined in Rule 12b-2 of the Exchange Act). Yes \u2610 No \u2612 As of August 19, 2026, the Company had 1,303,911 shares of common stock, $0.0001 par value, issued and 1,303,857 shares of common stock, $0.0001 par value, outstanding. LQR HOUSE INC. FORM 10-Q TABLE OF CONTENTS PART I. FINANCIAL INFORMATION ITEM 1. Financial Statements \u2013 ||| [0001213900-26-091661 10-Q 2026-08-19] abilities 50,117,162 1,899,820 Commitments and contingencies (Note 17) Stockholders\u2019 equity: Common stock, $ 0.0001 par value, 1,500,000,000 shares authorized, 215,335 and 213,717 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively 21 21 Additional paid-in capital 97,875,452 97,709,453 Treasury stock, at cost ( 54 shares) ( 547,415 )",
   "supporting_passages": [
    "[0001213900-26-091661 10-Q 2026-08-19] s defined in Rule 12b-2 of the Exchange Act). Yes \u2610 No \u2612 As of August 19, 2026, the Company had 1,303,911 shares of common stock, $0.0001 par value, issued and 1,303,857 shares of common stock, $0.0001 par value, outstanding. LQR HOUSE INC. FORM 10-Q TABLE OF CONTENTS PART I. FINANCIAL INFORMATION ITEM 1. Financial Statements \u2013",
    "[0001213900-26-091661 10-Q 2026-08-19] abilities 50,117,162 1,899,820 Commitments and contingencies (Note 17) Stockholders\u2019 equity: Common stock, $ 0.0001 par value, 1,500,000,000 shares authorized, 215,335 and 213,717 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively 21 21 Additional paid-in capital 97,875,452 97,709,453 Treasury stock, at cost ( 54 shares) ( 547,415 )"
   ],
   "xbrl_facts": [
    {
     "tag": "EntityCommonStockSharesOutstanding",
     "value": 1303857,
     "period_start": null,
     "period_end": "2026-08-19",
     "accession": "0001213900-26-091661"
    },
    {
     "tag": "CommonStockSharesIssued",
     "value": 215335,
     "period_start": null,
     "period_end": "2026-06-30",
     "accession": "0001213900-26-091661"
    },
    {
     "tag": "CommonStockSharesOutstanding",
     "value": 215335,
     "period_start": null,
     "period_end": "2026-06-30",
     "accession": "0001213900-26-091661"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "The two counts differ by 6.1x because of post-quarter issuance; a tool that reports only one, or treats the cover count as the quarter-end count, misses half the answer. A later Q3 10-Q filed after October 31, 2026 must not be used.",
   "difficulty_features": [
    "cover vs balance sheet",
    "as-of discipline"
   ],
   "question": "In the most recent Form 10-Q that LQR House (YHC) had filed on or before October 31, 2026, how many shares of common stock were outstanding as of the cover-page date, and how many were issued and outstanding on the balance sheet at the end of the quarter?"
  },
  {
   "id": "R3-20",
   "ticker": "RR",
   "category": "other_amended",
   "answer": "$49.182 million (as restated in the Form 10-K/A filed August 7, 2026); originally reported as $15.754 million.",
   "accepted_variants": [
    "$49,182",
    "$49.2 million",
    "49,182,000"
   ],
   "as_of": "Fiscal year ended September 30, 2025; amendments through October 31, 2026",
   "primary_source": [
    {
     "accession": "0001213900-26-086751",
     "form": "10-K/A",
     "filing_date": "2026-08-07",
     "url": "https://www.sec.gov/Archives/edgar/data/1963685/000121390026086751/ea0298288-10ka1_richtech.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1963685/000121390026086751/",
     "role": "10-K/A"
    }
   ],
   "supporting_passage": "[0001213900-26-086751 10-K/A 2026-08-07] ited Consolidated Statement of Cash Flows \u2013 Fiscal Year Ended September 30, 2025 Line item As Previously Reported on 10-K Restatement Adjustment ID As Restated Consolidated net loss ( 15,754 ) ( 33,428 ) * ( 49,182 ) Depreciation and amortization 2,319 ( 932 ) 7,9 1,387 Change in fair value of warrant liability - 34,172 2,3 34,172 Issuance costs related to warr ||| [0001213900-26-086751 10-K/A 2026-08-07] r expenses (32,078 ) 6,838 (38,916 ) Loss before income tax expense (49,278 ) (942 ) (48,336 ) Income tax benefit/(expense) 96 (426 ) 522 Consolidated net loss (49,182 ) (1,368 ) (47,816 ) Less: Net loss Attributable to Non-Controlling Interest (108 ) - (108 ) Net loss attributable to common stockholders $ (49,074 ) $ (1,368 ) ",
   "supporting_passages": [
    "[0001213900-26-086751 10-K/A 2026-08-07] ited Consolidated Statement of Cash Flows \u2013 Fiscal Year Ended September 30, 2025 Line item As Previously Reported on 10-K Restatement Adjustment ID As Restated Consolidated net loss ( 15,754 ) ( 33,428 ) * ( 49,182 ) Depreciation and amortization 2,319 ( 932 ) 7,9 1,387 Change in fair value of warrant liability - 34,172 2,3 34,172 Issuance costs related to warr",
    "[0001213900-26-086751 10-K/A 2026-08-07] r expenses (32,078 ) 6,838 (38,916 ) Loss before income tax expense (49,278 ) (942 ) (48,336 ) Income tax benefit/(expense) 96 (426 ) 522 Consolidated net loss (49,182 ) (1,368 ) (47,816 ) Less: Net loss Attributable to Non-Controlling Interest (108 ) - (108 ) Net loss attributable to common stockholders $ (49,074 ) $ (1,368 ) "
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "The restatement more than tripled the loss (adjustment of $33.428 million); the original FY2025 10-K showed $15.754 million. Richtech's fiscal year ends September 30, so 'fiscal 2025' is the year ended September 30, 2025.",
   "difficulty_features": [
    "amended filing supersedes original"
   ],
   "question": "What was Richtech Robotics' (RR) consolidated net loss for the fiscal year ended September 30, 2025, as currently reported after any restatement filed on or before October 31, 2026?"
  },
  {
   "id": "R3-21",
   "ticker": "DCOY",
   "category": "dilution",
   "answer": "$3.25 per share, reduced from the original $5.91 in the September 22, 2026 inducement. The Series B Milestone Warrants (1,184,434 shares) were exercised in full for cash at the reduced $3.25, and Decoy issued new warrants for 2,368,868 shares at $3.25.",
   "accepted_variants": [
    "$3.25",
    "1,184,434",
    "2,368,868"
   ],
   "as_of": "September 30, 2026",
   "primary_source": [
    {
     "accession": "0001193125-26-286737",
     "form": "8-K",
     "filing_date": "2026-06-29",
     "url": "https://www.sec.gov/Archives/edgar/data/1615219/000119312526286737/dcoy-20260626.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1615219/000119312526286737/",
     "role": "original terms"
    },
    {
     "accession": "0001615219-26-000019",
     "form": "8-K",
     "filing_date": "2026-09-23",
     "url": "https://www.sec.gov/Archives/edgar/data/1615219/000161521926000019/dcoy-20260922.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1615219/000161521926000019/",
     "role": "inducement 8-K"
    }
   ],
   "supporting_passage": "[0001193125-26-286737 8-K 2026-06-29] al to 100%, 200% and 200%, respectively, of the number of Shares (and shares underlying any Pre-Funded Warrants) purchased by the Purchaser, in each case at an exercise price of $5.91 per share, subject to adjustment. The aggregate gross proceeds to the Company from the Private Placement are expected to be approximately $3.5 million, before deducting  ||| [0001615219-26-000019 8-K 2026-09-23] , par value $0.0001 per share (the \u201cCommon Stock\u201d). Pursuant to the Inducement Letter, the Company agreed to reduce the exercise price of the Existing Warrants from $5.91 per share to $3.25 per share. In connection with the transaction, the exercise price of the Company's outstanding Series A Milestone Warrants and Series C Milestone Warrants was also reduc ||| [0001615219-26-000019 8-K 2026-09-23] ise price of the Existing Warrants from $5.91 per share to $3.25 per share. In connection with the transaction, the exercise price of the Company's outstanding Series A Milestone Warrants and Series C Milestone Warrants was also reduced from $5.91 per share to $3.25 per share; the other terms of such warrants were not amended. The Existing Warrants were exercised in full on September 22, 2026, and the transaction closed on September ||| [0001615219-26-000019 8-K 2026-09-23] sting Warrants, on September 23, 2026, the Company issued to the Holder in a private placement new unregistered warrants (the \u201cNew Warrants\u201d) to purchase up to 2,368,868 shares of Common Stock, representing 200% of the number of shares underlying the exercised Existing Warrants. The New Warrants have an exercise price of $3.25 ",
   "supporting_passages": [
    "[0001193125-26-286737 8-K 2026-06-29] al to 100%, 200% and 200%, respectively, of the number of Shares (and shares underlying any Pre-Funded Warrants) purchased by the Purchaser, in each case at an exercise price of $5.91 per share, subject to adjustment. The aggregate gross proceeds to the Company from the Private Placement are expected to be approximately $3.5 million, before deducting ",
    "[0001615219-26-000019 8-K 2026-09-23] , par value $0.0001 per share (the \u201cCommon Stock\u201d). Pursuant to the Inducement Letter, the Company agreed to reduce the exercise price of the Existing Warrants from $5.91 per share to $3.25 per share. In connection with the transaction, the exercise price of the Company's outstanding Series A Milestone Warrants and Series C Milestone Warrants was also reduc",
    "[0001615219-26-000019 8-K 2026-09-23] ise price of the Existing Warrants from $5.91 per share to $3.25 per share. In connection with the transaction, the exercise price of the Company's outstanding Series A Milestone Warrants and Series C Milestone Warrants was also reduced from $5.91 per share to $3.25 per share; the other terms of such warrants were not amended. The Existing Warrants were exercised in full on September 22, 2026, and the transaction closed on September",
    "[0001615219-26-000019 8-K 2026-09-23] sting Warrants, on September 23, 2026, the Company issued to the Holder in a private placement new unregistered warrants (the \u201cNew Warrants\u201d) to purchase up to 2,368,868 shares of Common Stock, representing 200% of the number of shares underlying the exercised Existing Warrants. The New Warrants have an exercise price of $3.25 "
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "The June 29, 2026 issuance 8-K states $5.91; the later inducement 8-K reprices the unexercised Series A and C as well. A tool reading only the issuance filing reports $5.91.",
   "difficulty_features": [
    "repricing in later filing",
    "multi-filing"
   ],
   "question": "As of September 30, 2026, what was the exercise price of the Series A and Series C Milestone Warrants that Decoy Therapeutics (DCOY) issued on June 29, 2026, and what happened to the Series B Milestone Warrants?"
  },
  {
   "id": "R3-22",
   "ticker": "KITT",
   "category": "reverse_split",
   "answer": "About 600,233 shares: the 1-for-8 split (effective April 17, 2026; 10-Qs restate the figure as 3,601,400) and the 1-for-6 split (effective September 24, 2026) give a combined factor of 48; 28,811,198 / 48 = 600,233.3 (3,601,400 / 6 = 600,233.3).",
   "accepted_variants": [
    "600,233",
    "600,234",
    "approximately 600,000",
    "factor of 48",
    "1-for-48"
   ],
   "as_of": "Splits effective after April 15, 2026 and on or before October 31, 2026",
   "primary_source": [
    {
     "accession": "0001849820-26-000051",
     "form": "10-K",
     "filing_date": "2026-04-15",
     "url": "https://www.sec.gov/Archives/edgar/data/1849820/000184982026000051/kitt-20251231.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1849820/000184982026000051/",
     "role": "original figure"
    },
    {
     "accession": "0001849820-26-000057",
     "form": "8-K",
     "filing_date": "2026-04-17",
     "url": "https://www.sec.gov/Archives/edgar/data/1849820/000184982026000057/kitt-20260416.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1849820/000184982026000057/",
     "role": "split 1"
    },
    {
     "accession": "0001849820-26-000090",
     "form": "10-Q",
     "filing_date": "2026-05-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1849820/000184982026000090/kitt-20260331.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1849820/000184982026000090/",
     "role": "restated for split 1"
    },
    {
     "accession": "0001849820-26-000142",
     "form": "8-K",
     "filing_date": "2026-09-23",
     "url": "https://www.sec.gov/Archives/edgar/data/1849820/000184982026000142/kitt-20260923.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1849820/000184982026000142/",
     "role": "split 2"
    }
   ],
   "supporting_passage": "[0001849820-26-000051 10-K 2026-04-15] ,154 and 0 issued and outstanding at December 31, 2025 and December 31, 2024 respectively. - - Common Stock, $ 0.0001 par value; 625,000,000 shares authorized, 28,811,198 and 1,084,655 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively.* 2,881 108 Additional paid-in capital 330,578,863 233,343 ||| [0001849820-26-000057 8-K 2026-04-17] [[DOC a2026-0415_reversesplitx.htm]]  EX-99.1 3 a2026-0415_reversesplitx.htm EX-99.1 a2026-0415_reversesplitx Nauticus Robotics Announces 1-for-8 Reverse Stock Split HOUSTON, April 17, 2026. Nauticus Robotics, Inc. (NASDAQ: KITT, \u201cNauticus\u201d or the \u201cCompany\u201d) today announced that it will proceed with a 1-for-8 reverse stock  ||| [0001849820-26-000057 8-K 2026-04-17] 5_reversesplitx.htm]]  EX-99.1 3 a2026-0415_reversesplitx.htm EX-99.1 a2026-0415_reversesplitx Nauticus Robotics Announces 1-for-8 Reverse Stock Split HOUSTON, April 17, 2026. Nauticus Robotics, Inc. (NASDAQ: KITT, \u201cNauticus\u201d or the \u201cCompany\u201d) today announced that it will proceed with a 1-for-8 reverse stock split (\u201cReverse Split\u201d)  ||| [0001849820-26-000090 10-Q 2026-05-14]  and outstanding at March 31, 2026 and December 31, 2025, respectively. - - 1 Common stock, $ 0.0001 par value; 625,000,000 shares authorized and 4,291,998 and 3,601,400 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively.* 429 360 Additional paid-in capital 337,266,475 330,581,384 Accumulated ot ||| [0001849820-26-000142 8-K 2026-09-23]  its Second Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the \"Certificate of Amendment\") to effect a 1-for-6 reverse stock split (the \u201cReverse Stock Split\u201d) of the shares of the Company's common stock, par value $0.0001 per share. The Certificate of Amendment becomes effective at 8:01 PM ||| [0001849820-26-000142 8-K 2026-09-23] duly adopted in accordance with the provisions of Section 242 of the DGCL. 4. This Certificate of Amendment shall become effective at 8:01 p.m. Eastern Time on September 24, 2026. [SIGNATURE PAGE FOLLOWS] IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be executed by its duly authorized officer on Septemb",
   "supporting_passages": [
    "[0001849820-26-000051 10-K 2026-04-15] ,154 and 0 issued and outstanding at December 31, 2025 and December 31, 2024 respectively. - - Common Stock, $ 0.0001 par value; 625,000,000 shares authorized, 28,811,198 and 1,084,655 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively.* 2,881 108 Additional paid-in capital 330,578,863 233,343",
    "[0001849820-26-000057 8-K 2026-04-17] [[DOC a2026-0415_reversesplitx.htm]]  EX-99.1 3 a2026-0415_reversesplitx.htm EX-99.1 a2026-0415_reversesplitx Nauticus Robotics Announces 1-for-8 Reverse Stock Split HOUSTON, April 17, 2026. Nauticus Robotics, Inc. (NASDAQ: KITT, \u201cNauticus\u201d or the \u201cCompany\u201d) today announced that it will proceed with a 1-for-8 reverse stock ",
    "[0001849820-26-000057 8-K 2026-04-17] 5_reversesplitx.htm]]  EX-99.1 3 a2026-0415_reversesplitx.htm EX-99.1 a2026-0415_reversesplitx Nauticus Robotics Announces 1-for-8 Reverse Stock Split HOUSTON, April 17, 2026. Nauticus Robotics, Inc. (NASDAQ: KITT, \u201cNauticus\u201d or the \u201cCompany\u201d) today announced that it will proceed with a 1-for-8 reverse stock split (\u201cReverse Split\u201d) ",
    "[0001849820-26-000090 10-Q 2026-05-14]  and outstanding at March 31, 2026 and December 31, 2025, respectively. - - 1 Common stock, $ 0.0001 par value; 625,000,000 shares authorized and 4,291,998 and 3,601,400 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively.* 429 360 Additional paid-in capital 337,266,475 330,581,384 Accumulated ot",
    "[0001849820-26-000142 8-K 2026-09-23]  its Second Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the \"Certificate of Amendment\") to effect a 1-for-6 reverse stock split (the \u201cReverse Stock Split\u201d) of the shares of the Company's common stock, par value $0.0001 per share. The Certificate of Amendment becomes effective at 8:01 PM",
    "[0001849820-26-000142 8-K 2026-09-23] duly adopted in accordance with the provisions of Section 242 of the DGCL. 4. This Certificate of Amendment shall become effective at 8:01 p.m. Eastern Time on September 24, 2026. [SIGNATURE PAGE FOLLOWS] IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be executed by its duly authorized officer on Septemb"
   ],
   "xbrl_facts": [
    {
     "tag": "CommonStockSharesIssued",
     "value": 28811198,
     "period_start": null,
     "period_end": "2025-12-31",
     "accession": "0001849820-26-000051"
    },
    {
     "tag": "CommonStockSharesOutstanding",
     "value": 28811198,
     "period_start": null,
     "period_end": "2025-12-31",
     "accession": "0001849820-26-000051"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Two later splits must both be applied (one 8-K each); the 2024 1-for-36 and 2025 1-for-9 splits are already in the 10-K figure. No filing yet restates the figure for the September split, so the answer is arithmetic from filed figures (accept 600,233 or 600,234 for rounding).",
   "difficulty_features": [
    "split-adjusting an old figure",
    "multi-filing",
    "arithmetic"
   ],
   "question": "Nauticus Robotics (KITT) reported 28,811,198 shares of common stock outstanding at December 31, 2025 in its FY2025 Form 10-K (filed April 15, 2026). Adjusted for every reverse stock split it effected after that filing and on or before October 31, 2026, what is the equivalent share count, and which splits apply?"
  },
  {
   "id": "R3-23",
   "ticker": "TELO",
   "category": "cash",
   "answer": "approximately $4.5 million ($4,515,704) at September 30, 2026 (10-Q for the quarter ended September 30, 2026); management expects it to fund operations into the fourth quarter of 2027. The prior quarter's 10-Q had said through the first quarter of 2027.",
   "accepted_variants": [
    "approximately $4.5 million",
    "fourth quarter of 2027"
   ],
   "as_of": "September 30, 2026; reports filed on or before November 10, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-050489",
     "form": "10-Q",
     "filing_date": "2026-11-06",
     "url": "https://www.sec.gov/Archives/edgar/data/1971532/000149315226050489/form10-q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1971532/000149315226050489/",
     "role": "Q3 2026 10-Q"
    },
    {
     "accession": "0001493152-26-037854",
     "form": "10-Q",
     "filing_date": "2026-08-13",
     "url": "https://www.sec.gov/Archives/edgar/data/1971532/000149315226037854/form10-q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1971532/000149315226037854/",
     "role": "trap: superseded Q2 guidance"
    }
   ],
   "supporting_passage": "[0001493152-26-050489 10-Q 2026-11-06]  of approximately $3.7 million for the nine months ended September 30, 2026 and an accumulated deficit of approximately $44.4 million as of September 30, 2026. As of September 30, 2026, we had cash and cash equivalents of approximately $4.5 million. We currently expect that our cash and cash equivalents will be sufficient to fund our operations, development plans, and capital expenditures into the fourth  ||| [0001493152-26-050489 10-Q 2026-11-06] ely $4.5 million. We currently expect that our cash and cash equivalents will be sufficient to fund our operations, development plans, and capital expenditures into the fourth quarter of 2027. We did not have any material non-cancellable contractual obligations as of September 30, 2026. Cash Flows The following table provides information regarding o ||| [0001493152-26-037854 10-Q 2026-08-13] ely $5.2 million. We currently expect that our cash and cash equivalents will be sufficient to fund our operations, development plans, and capital expenditures through the first quarter of 2027. We did not have any material non-cancellable contractual obligations as of June 30, 2026. Cash Flows The following table provides information regarding our ca",
   "supporting_passages": [
    "[0001493152-26-050489 10-Q 2026-11-06]  of approximately $3.7 million for the nine months ended September 30, 2026 and an accumulated deficit of approximately $44.4 million as of September 30, 2026. As of September 30, 2026, we had cash and cash equivalents of approximately $4.5 million. We currently expect that our cash and cash equivalents will be sufficient to fund our operations, development plans, and capital expenditures into the fourth ",
    "[0001493152-26-050489 10-Q 2026-11-06] ely $4.5 million. We currently expect that our cash and cash equivalents will be sufficient to fund our operations, development plans, and capital expenditures into the fourth quarter of 2027. We did not have any material non-cancellable contractual obligations as of September 30, 2026. Cash Flows The following table provides information regarding o",
    "[0001493152-26-037854 10-Q 2026-08-13] ely $5.2 million. We currently expect that our cash and cash equivalents will be sufficient to fund our operations, development plans, and capital expenditures through the first quarter of 2027. We did not have any material non-cancellable contractual obligations as of June 30, 2026. Cash Flows The following table provides information regarding our ca"
   ],
   "xbrl_facts": [
    {
     "tag": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "value": 4515704,
     "period_start": null,
     "period_end": "2026-09-30",
     "accession": "0001493152-26-050489"
    },
    {
     "tag": "CashAndCashEquivalentsAtCarryingValue",
     "value": 4515704,
     "period_start": null,
     "period_end": "2026-09-30",
     "accession": "0001493152-26-050489"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Runway guidance changed between the Q2 10-Q ('through the first quarter of 2027') and the Q3 10-Q ('into the fourth quarter of 2027'); a tool that relies on the August filing gives stale guidance and a June 30 balance.",
   "difficulty_features": [
    "find newest filing",
    "superseded guidance"
   ],
   "question": "Based on the most recent quarterly report Telomir Pharmaceuticals (TELO) had filed on or before November 10, 2026: what were its cash and cash equivalents at quarter end, and through when did management say its cash would fund operations?"
  },
  {
   "id": "R3-24",
   "ticker": "HLSQ",
   "category": "shares_float",
   "answer": "Cover: 26,723,870 shares outstanding as of August 18, 2026. Balance sheet: 12,590,641 shares at June 30, 2026 (10-Q for the quarter ended June 30, 2026).",
   "accepted_variants": [
    "26,723,870",
    "12,590,641"
   ],
   "as_of": "Cover date August 18, 2026; balance sheet June 30, 2026",
   "primary_source": [
    {
     "accession": "0001213900-26-091780",
     "form": "10-Q",
     "filing_date": "2026-08-19",
     "url": "https://www.sec.gov/Archives/edgar/data/1739174/000121390026091780/ea0302351-10q_biomxinc.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1739174/000121390026091780/",
     "role": "Q2 2026 10-Q"
    }
   ],
   "supporting_passage": "[0001213900-26-091780 10-Q 2026-08-19] te by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes \u2610 No \u2612 As of August 18, 2026, the registrant had 26,723,870 shares of common stock, $0.0001 par value per share, issued and outstanding. BIOMX, INC. Form 10-Q June 30, 2026 Page PART I \u2014 FINANCIAL INFORMATION Item 1 \u2013 U ||| [0001213900-26-091780 10-Q 2026-08-19] 2 18,617 Common stock, $ 0.0001 par value (\u201cCommon Stock\u201d); Authorized - 750,000,000 shares as of June 30, 2026 and December 31, 2025. Issued and outstanding \u2013 12,590,641 and 1,593,703 as of June 30, 2026 and December 31, 2025, respectively. 8 7 Receivables on account of shares ( 300 ) - Additional paid-in capital 244,474 196,97",
   "supporting_passages": [
    "[0001213900-26-091780 10-Q 2026-08-19] te by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes \u2610 No \u2612 As of August 18, 2026, the registrant had 26,723,870 shares of common stock, $0.0001 par value per share, issued and outstanding. BIOMX, INC. Form 10-Q June 30, 2026 Page PART I \u2014 FINANCIAL INFORMATION Item 1 \u2013 U",
    "[0001213900-26-091780 10-Q 2026-08-19] 2 18,617 Common stock, $ 0.0001 par value (\u201cCommon Stock\u201d); Authorized - 750,000,000 shares as of June 30, 2026 and December 31, 2025. Issued and outstanding \u2013 12,590,641 and 1,593,703 as of June 30, 2026 and December 31, 2025, respectively. 8 7 Receivables on account of shares ( 300 ) - Additional paid-in capital 244,474 196,97"
   ],
   "xbrl_facts": [
    {
     "tag": "EntityCommonStockSharesOutstanding",
     "value": 26723870,
     "period_start": null,
     "period_end": "2026-08-18",
     "accession": "0001213900-26-091780"
    },
    {
     "tag": "CommonStockSharesIssued",
     "value": 12590641,
     "period_start": null,
     "period_end": "2026-06-30",
     "accession": "0001213900-26-091780"
    },
    {
     "tag": "CommonStockSharesOutstanding",
     "value": 12590641,
     "period_start": null,
     "period_end": "2026-06-30",
     "accession": "0001213900-26-091780"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "The two counts differ by 2.1x because of post-quarter issuance; a tool that reports only one, or treats the cover count as the quarter-end count, misses half the answer. A later Q3 10-Q filed after October 31, 2026 must not be used.",
   "difficulty_features": [
    "cover vs balance sheet",
    "as-of discipline"
   ],
   "question": "In the most recent Form 10-Q that BiomX, Inc. (now Tessera Defense & Homeland Security) (HLSQ) had filed on or before October 31, 2026, how many shares of common stock were outstanding as of the cover-page date, and how many were issued and outstanding on the balance sheet at the end of the quarter?"
  },
  {
   "id": "R3-25",
   "ticker": "ROLR",
   "category": "other_amended",
   "answer": "$4.333 million (as restated in the Form 10-Q/A filed October 16, 2026); originally reported as $5.336 million.",
   "accepted_variants": [
    "$4,333",
    "$4.3 million",
    "4,333,000"
   ],
   "as_of": "Six months ended June 30, 2026; amendments through October 31, 2026",
   "primary_source": [
    {
     "accession": "0001753926-26-001960",
     "form": "10-Q/A",
     "filing_date": "2026-10-16",
     "url": "https://www.sec.gov/Archives/edgar/data/1947210/000175392626001960/rolr-20260630.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1947210/000175392626001960/",
     "role": "10-Q/A"
    },
    {
     "accession": "0001753926-26-001419",
     "form": "10-Q",
     "filing_date": "2026-08-11",
     "url": "https://www.sec.gov/Archives/edgar/data/1947210/000175392626001419/rolr-20260630.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1947210/000175392626001419/",
     "role": "trap: original 10-Q"
    }
   ],
   "supporting_passage": "[0001753926-26-001960 10-Q/A 2026-10-16] ed Six months ended June 30, 2026 Revenue $ 6,175 $ \u2014 $ 6,175 General and administrative expense 7,879 (1,003) 6,876 Loss from operations (5,467) 1,003 (4,464) Net loss (5,336) 1,003 (4,333) Basic and diluted net loss per share $ (0.50) $ 0.09 $ (0.41) Net cash used in operating activities (5,873) \u2014 (5,873) Three months ended June 30, 2026 Net loss ||| [0001753926-26-001419 10-Q 2026-08-11] Loss before income taxes ( 2,339 ) ( 1,120 ) ( 5,289 ) ( 4,828 ) Income tax expense 31 37 47 54 Net loss from continuing operations $ ( 2,370 ) $ ( 1,157 ) $ ( 5,336 ) $ ( 4,882 ) Net income from discontinued operations, net of taxes $ \u2014 $ 565 $ \u2014 $ 1,014 Net loss $ ( 2,370 ) $ ( 592 ) $ ( 5,336 ) $ ( 3,868 ) Other comprehe",
   "supporting_passages": [
    "[0001753926-26-001960 10-Q/A 2026-10-16] ed Six months ended June 30, 2026 Revenue $ 6,175 $ \u2014 $ 6,175 General and administrative expense 7,879 (1,003) 6,876 Loss from operations (5,467) 1,003 (4,464) Net loss (5,336) 1,003 (4,333) Basic and diluted net loss per share $ (0.50) $ 0.09 $ (0.41) Net cash used in operating activities (5,873) \u2014 (5,873) Three months ended June 30, 2026 Net loss",
    "[0001753926-26-001419 10-Q 2026-08-11] Loss before income taxes ( 2,339 ) ( 1,120 ) ( 5,289 ) ( 4,828 ) Income tax expense 31 37 47 54 Net loss from continuing operations $ ( 2,370 ) $ ( 1,157 ) $ ( 5,336 ) $ ( 4,882 ) Net income from discontinued operations, net of taxes $ \u2014 $ 565 $ \u2014 $ 1,014 Net loss $ ( 2,370 ) $ ( 592 ) $ ( 5,336 ) $ ( 3,868 ) Other comprehe"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "The restatement REDUCES the loss (G&A cut by $1,003 thousand); the original August 11, 2026 10-Q shows $5.336 million. The three-month figure ($2.370 million) was unchanged, so only the six-month figure tests the amendment.",
   "difficulty_features": [
    "amended filing supersedes original",
    "direction of restatement"
   ],
   "question": "What was High Roller Technologies' (ROLR) net loss for the six months ended June 30, 2026, as currently reported after any amendment filed on or before October 31, 2026?"
  },
  {
   "id": "R3-26",
   "ticker": "WWR",
   "category": "dilution",
   "answer": "Approximately $70.6 million remaining under the ATM Sales Agreement and approximately $26.2 million under the 2024 Lincoln Park purchase agreement.",
   "accepted_variants": [
    "$70.6 million",
    "$26.2 million"
   ],
   "as_of": "June 30, 2026",
   "primary_source": [
    {
     "accession": "0001104659-26-092955",
     "form": "10-Q",
     "filing_date": "2026-08-10",
     "url": "https://www.sec.gov/Archives/edgar/data/839470/000110465926092955/wwr-20260630x10q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/839470/000110465926092955/",
     "role": "Q2 2026 10-Q"
    }
   ],
   "supporting_passage": "[0001104659-26-092955 10-Q 2026-08-10] the Company sold 1.0 million shares of Common Stock for net proceeds of $ 1.2 million pursuant to the ATM Sales Agreement. As of June 30, 2026, the Company has approximately $ 70.6 million remaining available for future sales under the ATM Sales Agreement and approximately $ 26.2 million remaining available for future sales under the 2024 Lincoln Park PA. See Note 7 Stockholders\u2019 Equity for further details regarding the Company\u2019s equity financing agreements. While the Company has advanced its business plan and ",
   "supporting_passages": [
    "[0001104659-26-092955 10-Q 2026-08-10] the Company sold 1.0 million shares of Common Stock for net proceeds of $ 1.2 million pursuant to the ATM Sales Agreement. As of June 30, 2026, the Company has approximately $ 70.6 million remaining available for future sales under the ATM Sales Agreement and approximately $ 26.2 million remaining available for future sales under the 2024 Lincoln Park PA. See Note 7 Stockholders\u2019 Equity for further details regarding the Company\u2019s equity financing agreements. While the Company has advanced its business plan and "
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Two separate facilities; a tool that reports one (or adds them as one ATM figure) is incomplete.",
   "difficulty_features": [
    "two facilities",
    "footnote reading"
   ],
   "question": "As of June 30, 2026, how much equity capacity did Westwater Resources (WWR) have remaining under its ATM sales agreement and under its Lincoln Park purchase agreement, respectively?"
  },
  {
   "id": "R3-27",
   "ticker": "SLXN",
   "category": "reverse_split",
   "answer": "Three: 1-for-9 (November 2024), 1-for-15 (July 2025) and 1-for-10 (effective after the close on May 28, 2026). Cumulative factor 9 x 15 x 10 = 1,350.",
   "accepted_variants": [
    "3 reverse splits",
    "1,350",
    "1-for-1,350"
   ],
   "as_of": "Window January 1, 2024 to October 31, 2026",
   "primary_source": [
    {
     "accession": "0001178913-26-004128",
     "form": "8-K",
     "filing_date": "2026-08-13",
     "url": "https://www.sec.gov/Archives/edgar/data/2022416/000117891326004128/zk2635957.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/2022416/000117891326004128/",
     "role": "three splits summarised"
    },
    {
     "accession": "0001178913-26-002988",
     "form": "8-K",
     "filing_date": "2026-05-29",
     "url": "https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/zk2635442.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/",
     "role": "split 3 8-K"
    },
    {
     "accession": "0001178913-26-005089",
     "form": "8-K",
     "filing_date": "2026-11-09",
     "url": "https://www.sec.gov/Archives/edgar/data/2022416/000117891326005089/zk2636370.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/2022416/000117891326005089/",
     "role": "trap: outside window"
    }
   ],
   "supporting_passage": "[0001178913-26-004128 8-K 2026-08-13] hares at an exercise price of $3.39 or 3.39 NIS per share *** All share amounts have been adjusted (in the case of prior periods, retroactively) to reflect the 1-for-9, 1-for-15 and 1-for-10 reverse share splits effected in November 2024, July 2025 and May 2026, respectively, as discussed in Note 1)e( **** Net of 3 treasury shares held by the Company as of December 31, 2024 The accompanying notes are an integral part  ||| [0001178913-26-002988 8-K 2026-05-29] capital of the Company (after increase pursuant to the adoption of the Authorized Share Capital Increase Proposal at the Meeting) be consolidated at a ratio of 1-for-10 (subject to reduction of that ratio to the extent needed to maintain a sufficient number of publicly held shares as required under the Nasdaq listing rules) as ||| [0001178913-26-002988 8-K 2026-05-29] en (10) pre-Reverse Share Split shares and the Reverse Share Split became effective following the close of trading on the Nasdaq Capital Market (\u201c Nasdaq \u201d) on May 28, 2026 (the \u201c Effective Date \u201d). The Company\u2019s ordinary shares will begin trading on Nasdaq on a post-Reverse Share Split basis under the Company\u2019s existing trade sym ||| [0001178913-26-005089 8-K 2026-11-09] [[DOC exhibit_99-1.htm]]  EX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1 Exhibit 99.1 Silexion Therapeutics Announces 1-for-24 Reverse Share Split Trading on a split-adjusted basis will begin at market open on November 11, 2026. This adjustment is expected to help Silexion regain compl ||| [0001178913-26-005089 8-K 2026-11-09] KRAS-driven cancers, today announced a 1-for-24 reverse share split of its ordinary shares. The reverse share split will become effective after market close on November 10, 2026, and the Company\u2019s ordinary shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at market open on November 11, 2026, under",
   "supporting_passages": [
    "[0001178913-26-004128 8-K 2026-08-13] hares at an exercise price of $3.39 or 3.39 NIS per share *** All share amounts have been adjusted (in the case of prior periods, retroactively) to reflect the 1-for-9, 1-for-15 and 1-for-10 reverse share splits effected in November 2024, July 2025 and May 2026, respectively, as discussed in Note 1)e( **** Net of 3 treasury shares held by the Company as of December 31, 2024 The accompanying notes are an integral part ",
    "[0001178913-26-002988 8-K 2026-05-29] capital of the Company (after increase pursuant to the adoption of the Authorized Share Capital Increase Proposal at the Meeting) be consolidated at a ratio of 1-for-10 (subject to reduction of that ratio to the extent needed to maintain a sufficient number of publicly held shares as required under the Nasdaq listing rules) as",
    "[0001178913-26-002988 8-K 2026-05-29] en (10) pre-Reverse Share Split shares and the Reverse Share Split became effective following the close of trading on the Nasdaq Capital Market (\u201c Nasdaq \u201d) on May 28, 2026 (the \u201c Effective Date \u201d). The Company\u2019s ordinary shares will begin trading on Nasdaq on a post-Reverse Share Split basis under the Company\u2019s existing trade sym",
    "[0001178913-26-005089 8-K 2026-11-09] [[DOC exhibit_99-1.htm]]  EX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1 Exhibit 99.1 Silexion Therapeutics Announces 1-for-24 Reverse Share Split Trading on a split-adjusted basis will begin at market open on November 11, 2026. This adjustment is expected to help Silexion regain compl",
    "[0001178913-26-005089 8-K 2026-11-09] KRAS-driven cancers, today announced a 1-for-24 reverse share split of its ordinary shares. The reverse share split will become effective after market close on November 10, 2026, and the Company\u2019s ordinary shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at market open on November 11, 2026, under"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "A 1-for-24 split announced November 9, 2026 and effective after the close on November 10, 2026 is outside the window (including it gives 32,400). The October 26, 2026 shareholder-approval 8-K is not itself a split.",
   "difficulty_features": [
    "multi-filing",
    "date-window exclusion",
    "arithmetic"
   ],
   "question": "Between January 1, 2024 and October 31, 2026, how many reverse share splits did Silexion Therapeutics (SLXN) effect, at what ratios, and what is the cumulative factor?"
  },
  {
   "id": "R3-28",
   "ticker": "ALGS",
   "category": "cash",
   "answer": "$31.1 million at September 30, 2026 (10-Q for the quarter ended September 30, 2026); management expects it to fund operations into the first quarter of 2027. The prior quarter's 10-Q had said into the fourth quarter of 2026.",
   "accepted_variants": [
    "$31.1 million",
    "first quarter of 2027"
   ],
   "as_of": "September 30, 2026; reports filed on or before November 10, 2026",
   "primary_source": [
    {
     "accession": "0001193125-26-450798",
     "form": "10-Q",
     "filing_date": "2026-11-06",
     "url": "https://www.sec.gov/Archives/edgar/data/1799448/000119312526450798/algs-20260930.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1799448/000119312526450798/",
     "role": "Q3 2026 10-Q"
    },
    {
     "accession": "0001193125-26-336851",
     "form": "10-Q",
     "filing_date": "2026-08-06",
     "url": "https://www.sec.gov/Archives/edgar/data/1799448/000119312526336851/algs-20260630.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1799448/000119312526336851/",
     "role": "trap: superseded Q2 guidance"
    }
   ],
   "supporting_passage": "[0001193125-26-450798 10-Q 2026-11-06] , that raise substantial doubt about its ability to continue as a going concern within one year of the date that the condensed financial statements are issued. As of September 30, 2026, the Company had cash and cash equivalents of $ 31.1 million and an accumulated deficit of $ 688.6 million . The Company has incurred recurring losses from operations and negative cash flows from operating activities. Th ||| [0001193125-26-450798 10-Q 2026-11-06] and negative cash flows from operating activities. The Company expects that its cash and cash equivalents will be sufficient to fund current planned operations into the first quarter of 2027, which is less than one year from the date of filing this Quarterly Report on Form 10-Q. The Company plans to raise substantial additional capital to continue  ||| [0001193125-26-336851 10-Q 2026-08-06]  and cash equivalents, in addition to the $ 25.0 million, net of tax, received from Amoytop in July 2026, will be sufficient to fund current planned operations into the fourth quarter of 2026, which is less than one year from the date of filing this Quarterly Report on Form 10-Q. The Company plans to raise substantial additional capital to continue ",
   "supporting_passages": [
    "[0001193125-26-450798 10-Q 2026-11-06] , that raise substantial doubt about its ability to continue as a going concern within one year of the date that the condensed financial statements are issued. As of September 30, 2026, the Company had cash and cash equivalents of $ 31.1 million and an accumulated deficit of $ 688.6 million . The Company has incurred recurring losses from operations and negative cash flows from operating activities. Th",
    "[0001193125-26-450798 10-Q 2026-11-06] and negative cash flows from operating activities. The Company expects that its cash and cash equivalents will be sufficient to fund current planned operations into the first quarter of 2027, which is less than one year from the date of filing this Quarterly Report on Form 10-Q. The Company plans to raise substantial additional capital to continue ",
    "[0001193125-26-336851 10-Q 2026-08-06]  and cash equivalents, in addition to the $ 25.0 million, net of tax, received from Amoytop in July 2026, will be sufficient to fund current planned operations into the fourth quarter of 2026, which is less than one year from the date of filing this Quarterly Report on Form 10-Q. The Company plans to raise substantial additional capital to continue "
   ],
   "xbrl_facts": [
    {
     "tag": "CashAndCashEquivalentsAtCarryingValue",
     "value": 31094000,
     "period_start": null,
     "period_end": "2026-09-30",
     "accession": "0001193125-26-450798"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Runway guidance changed between the Q2 10-Q ('into the fourth quarter of 2026') and the Q3 10-Q ('into the first quarter of 2027'); a tool that relies on the August filing gives stale guidance and a June 30 balance.",
   "difficulty_features": [
    "find newest filing",
    "superseded guidance"
   ],
   "question": "Based on the most recent quarterly report Aligos Therapeutics (ALGS) had filed on or before November 10, 2026: what were its cash and cash equivalents at quarter end, and through when did management say its cash would fund operations?"
  },
  {
   "id": "R3-29",
   "ticker": "SGLY",
   "category": "shares_float",
   "answer": "Approximately $4,600,110 as of December 31, 2025 (cover of the Form 10-K for the fiscal year ended June 30, 2026, filed September 29, 2026).",
   "accepted_variants": [
    "$4,600,110",
    "$4.6 million"
   ],
   "as_of": "December 31, 2025 (last business day of second fiscal quarter)",
   "primary_source": [
    {
     "accession": "0001213900-26-104650",
     "form": "10-K",
     "filing_date": "2026-09-29",
     "url": "https://www.sec.gov/Archives/edgar/data/1422892/000121390026104650/ea0305950-10k_singularity.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1422892/000121390026104650/",
     "role": "FY2026 10-K"
    }
   ],
   "supporting_passage": "[0001213900-26-104650 10-K 2026-09-29] any (as defined in Rule 12b-2 of the Act). Yes \u2610 No \u2612 The aggregate market value of voting and non-voting common stock held by non-affiliates of the registrant as of December 31, 2025 was approximately $ 4,600,110 . The number of shares of common stock outstanding as of September 28, 2026 was 5,403,788 . DOCUMENTS INCORPORATED BY REFERENCE: None. SINGULARITY FUTURE TECHN",
   "supporting_passages": [
    "[0001213900-26-104650 10-K 2026-09-29] any (as defined in Rule 12b-2 of the Act). Yes \u2610 No \u2612 The aggregate market value of voting and non-voting common stock held by non-affiliates of the registrant as of December 31, 2025 was approximately $ 4,600,110 . The number of shares of common stock outstanding as of September 28, 2026 was 5,403,788 . DOCUMENTS INCORPORATED BY REFERENCE: None. SINGULARITY FUTURE TECHN"
   ],
   "xbrl_facts": [
    {
     "tag": "EntityPublicFloat",
     "value": 4600110,
     "period_start": null,
     "period_end": "2025-12-31",
     "accession": "0001213900-26-104650"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Fiscal year ends June 30, so the float date is December 31, 2025, not June 30, 2026; the prior year's 10-K (FY June 30, 2025) carries a stale figure.",
   "difficulty_features": [
    "non-calendar fiscal year",
    "find latest annual report"
   ],
   "question": "According to the most recent annual report Singularity Future Technology (SGLY) had filed as of October 31, 2026, what was the aggregate market value of its common stock held by non-affiliates, and as of what date was it measured?"
  },
  {
   "id": "R3-30",
   "ticker": "CISO",
   "category": "other_8k",
   "answer": "December 28, 2026 (second 180-day compliance period granted June 30, 2026; the first period ran to June 29, 2026).",
   "accepted_variants": [
    "December 28, 2026"
   ],
   "as_of": "October 31, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-032157",
     "form": "8-K",
     "filing_date": "2026-07-06",
     "url": "https://www.sec.gov/Archives/edgar/data/1777319/000149315226032157/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1777319/000149315226032157/",
     "role": "extension 8-K"
    }
   ],
   "supporting_passage": "[0001493152-26-032157 8-K 2026-07-06] rice requirement for continued listing under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we had 180 calendar days, or until June 29, 2026, to regain compliance. On June 30, 2026, the Staff notified us that we are eligible for an additional 180 calendar day period, or until December 28, 2026, to r ||| [0001493152-26-032157 8-K 2026-07-06]  days, or until June 29, 2026, to regain compliance. On June 30, 2026, the Staff notified us that we are eligible for an additional 180 calendar day period, or until December 28, 2026, to regain compliance. The Staff\u2019s determination was based on our meeting the continued listing requirement for market value of publicly held shares and all ot",
   "supporting_passages": [
    "[0001493152-26-032157 8-K 2026-07-06] rice requirement for continued listing under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we had 180 calendar days, or until June 29, 2026, to regain compliance. On June 30, 2026, the Staff notified us that we are eligible for an additional 180 calendar day period, or until December 28, 2026, to r",
    "[0001493152-26-032157 8-K 2026-07-06]  days, or until June 29, 2026, to regain compliance. On June 30, 2026, the Staff notified us that we are eligible for an additional 180 calendar day period, or until December 28, 2026, to regain compliance. The Staff\u2019s determination was based on our meeting the continued listing requirement for market value of publicly held shares and all ot"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "The original deadline (June 29, 2026) is superseded; no later 8-K through October 31, 2026 reports regained compliance or a delisting determination.",
   "difficulty_features": [
    "superseded deadline"
   ],
   "question": "As of October 31, 2026, by what date did CISO Global (CISO) have to regain compliance with Nasdaq's $1.00 minimum bid price requirement?"
  },
  {
   "id": "R3-31",
   "ticker": "EZRA",
   "category": "dilution",
   "answer": "Approximately $456,000 after a further 74,251 shares were sold after June 30, 2026 (net proceeds about $167,000); at June 30, 2026 approximately $632,000 remained.",
   "accepted_variants": [
    "$456,000",
    "$632,000"
   ],
   "as_of": "Latest date disclosed in the 10-Q for the quarter ended June 30, 2026 (filed July 30, 2026)",
   "primary_source": [
    {
     "accession": "0001493152-26-035504",
     "form": "10-Q",
     "filing_date": "2026-07-30",
     "url": "https://www.sec.gov/Archives/edgar/data/1812727/000149315226035504/form10-q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1812727/000149315226035504/",
     "role": "Q2 2026 10-Q"
    }
   ],
   "supporting_passage": "[0001493152-26-035504 10-Q 2026-07-30] ended June 30, 2026, the Company sold 278,978 shares of Common Stock under the ATM Program for net proceeds of approximately $ 1,117,000 . As of June 30, 2026, approximately $ 632,000 of Common Stock remained available for issuance under the ATM Program. Subsequent to June 30, 2026, the Company sold an additional 74,251 shares of Common Stock under the ATM Program for net pro ||| [0001493152-26-035504 10-Q 2026-07-30] 026, approximately $ 632,000 of Common Stock remained available for issuance under the ATM Program. Subsequent to June 30, 2026, the Company sold an additional 74,251 shares of Common Stock under the ATM Program for net proceeds of approximately $ 167,000 , and approximately $ 456,000 of Common Stock remained available for issuance ||| [0001493152-26-035504 10-Q 2026-07-30] bsequent to June 30, 2026, the Company sold an additional 74,251 shares of Common Stock under the ATM Program for net proceeds of approximately $ 167,000 , and approximately $ 456,000 of Common Stock remained available for issuance thereafter. Series K Public Offering On January 29, 2026, the Company closed a registered public offering (the \u201cSeries K Public Offering\u201d) of 185,185 shares of its common",
   "supporting_passages": [
    "[0001493152-26-035504 10-Q 2026-07-30] ended June 30, 2026, the Company sold 278,978 shares of Common Stock under the ATM Program for net proceeds of approximately $ 1,117,000 . As of June 30, 2026, approximately $ 632,000 of Common Stock remained available for issuance under the ATM Program. Subsequent to June 30, 2026, the Company sold an additional 74,251 shares of Common Stock under the ATM Program for net pro",
    "[0001493152-26-035504 10-Q 2026-07-30] 026, approximately $ 632,000 of Common Stock remained available for issuance under the ATM Program. Subsequent to June 30, 2026, the Company sold an additional 74,251 shares of Common Stock under the ATM Program for net proceeds of approximately $ 167,000 , and approximately $ 456,000 of Common Stock remained available for issuance",
    "[0001493152-26-035504 10-Q 2026-07-30] bsequent to June 30, 2026, the Company sold an additional 74,251 shares of Common Stock under the ATM Program for net proceeds of approximately $ 167,000 , and approximately $ 456,000 of Common Stock remained available for issuance thereafter. Series K Public Offering On January 29, 2026, the Company closed a registered public offering (the \u201cSeries K Public Offering\u201d) of 185,185 shares of its common"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "The quarter-end figure ($632,000) is superseded within the same filing by the subsequent-events figure; the question asks for both, so a tool must read past the first number.",
   "difficulty_features": [
    "subsequent-event update",
    "footnote reading"
   ],
   "question": "According to the most recent quarterly report Reliance Global Group (EZRA) had filed on or before October 31, 2026, how much remained available under its ATM program as of the latest date that report discloses, and how much had remained at quarter end?"
  },
  {
   "id": "R3-32",
   "ticker": "NXXT",
   "category": "reverse_split",
   "answer": "Two: 1-for-10 effective September 14, 2026 and another 1-for-10 effective October 30, 2026. Cumulative factor 100 (1-for-100).",
   "accepted_variants": [
    "2 reverse splits",
    "1-for-100",
    "100"
   ],
   "as_of": "Window January 1, 2026 to October 31, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-042576",
     "form": "8-K",
     "filing_date": "2026-09-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1817004/000149315226042576/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1817004/000149315226042576/",
     "role": "split 1"
    },
    {
     "accession": "0001493152-26-049449",
     "form": "8-K",
     "filing_date": "2026-10-30",
     "url": "https://www.sec.gov/Archives/edgar/data/1817004/000149315226049449/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1817004/000149315226049449/",
     "role": "split 2"
    },
    {
     "accession": "0001493152-26-050459",
     "form": "8-K",
     "filing_date": "2026-11-06",
     "url": "https://www.sec.gov/Archives/edgar/data/1817004/000149315226050459/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1817004/000149315226050459/",
     "role": "confirmation"
    }
   ],
   "supporting_passage": "[0001493152-26-042576 8-K 2026-09-14] \u201d or the \u201cCompany\u201d), a pioneer in AI-driven energy innovation transforming how energy is produced, managed and delivered, today announced that it will effect a 1-for-10 reverse split (\u201creverse stock split\u201d) of its shares of common stock that will become effective on September 14, 2026 at 12:00 a.m. (Eastern Time). The Company\u2019s common stock ||| [0001493152-26-042576 8-K 2026-09-14] and delivered, today announced that it will effect a 1-for-10 reverse split (\u201creverse stock split\u201d) of its shares of common stock that will become effective on September 14, 2026 at 12:00 a.m. (Eastern Time). The Company\u2019s common stock will continue to trade on Nasdaq under the symbol \u201cNXXT\u201d and will begin trading on a split-adjusted ba ||| [0001493152-26-049449 8-K 2026-10-30] \u201d or the \u201cCompany\u201d), a pioneer in AI-driven energy innovation transforming how energy is produced, managed and delivered, today announced that it will effect a 1-for-10 reverse split (\u201creverse stock split\u201d) of its shares of common stock that will become effective on October 30, 2026 at 12:01 a.m. (Eastern Time). The Company\u2019s common stock w ||| [0001493152-26-049449 8-K 2026-10-30] and delivered, today announced that it will effect a 1-for-10 reverse split (\u201creverse stock split\u201d) of its shares of common stock that will become effective on October 30, 2026 at 12:01 a.m. (Eastern Time). The Company\u2019s common stock will continue to trade on Nasdaq under the symbol \u201cNXXT\u201d and will begin trading on a split-adjusted ba ||| [0001493152-26-050459 8-K 2026-11-06] e described in the Company\u2019s Current Report on Form 8-K to be filed with the Securities and Exchange Commission. Separately, the Company\u2019s previously announced 1-for-10 reverse stock split became effective on Friday, October 30, 2026. The Company\u2019s common stock began trading on a split-adjusted basis on October 30 under the existing ticker symbol \u201cNXXT.\u201d The reverse split was intended to in",
   "supporting_passages": [
    "[0001493152-26-042576 8-K 2026-09-14] \u201d or the \u201cCompany\u201d), a pioneer in AI-driven energy innovation transforming how energy is produced, managed and delivered, today announced that it will effect a 1-for-10 reverse split (\u201creverse stock split\u201d) of its shares of common stock that will become effective on September 14, 2026 at 12:00 a.m. (Eastern Time). The Company\u2019s common stock",
    "[0001493152-26-042576 8-K 2026-09-14] and delivered, today announced that it will effect a 1-for-10 reverse split (\u201creverse stock split\u201d) of its shares of common stock that will become effective on September 14, 2026 at 12:00 a.m. (Eastern Time). The Company\u2019s common stock will continue to trade on Nasdaq under the symbol \u201cNXXT\u201d and will begin trading on a split-adjusted ba",
    "[0001493152-26-049449 8-K 2026-10-30] \u201d or the \u201cCompany\u201d), a pioneer in AI-driven energy innovation transforming how energy is produced, managed and delivered, today announced that it will effect a 1-for-10 reverse split (\u201creverse stock split\u201d) of its shares of common stock that will become effective on October 30, 2026 at 12:01 a.m. (Eastern Time). The Company\u2019s common stock w",
    "[0001493152-26-049449 8-K 2026-10-30] and delivered, today announced that it will effect a 1-for-10 reverse split (\u201creverse stock split\u201d) of its shares of common stock that will become effective on October 30, 2026 at 12:01 a.m. (Eastern Time). The Company\u2019s common stock will continue to trade on Nasdaq under the symbol \u201cNXXT\u201d and will begin trading on a split-adjusted ba",
    "[0001493152-26-050459 8-K 2026-11-06] e described in the Company\u2019s Current Report on Form 8-K to be filed with the Securities and Exchange Commission. Separately, the Company\u2019s previously announced 1-for-10 reverse stock split became effective on Friday, October 30, 2026. The Company\u2019s common stock began trading on a split-adjusted basis on October 30 under the existing ticker symbol \u201cNXXT.\u201d The reverse split was intended to in"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Two identical 1-for-10 splits seven weeks apart; a tool that finds one 8-K and stops answers 1-for-10. The second split took effect the day before the window closed.",
   "difficulty_features": [
    "multi-filing",
    "repeated identical event"
   ],
   "question": "How many reverse stock splits did NextNRG (NXXT) make effective between January 1, 2026 and October 31, 2026, and what is the cumulative factor?"
  },
  {
   "id": "R3-33",
   "ticker": "ELTX",
   "category": "cash",
   "answer": "$30.9 million at September 30, 2026 (10-Q for the quarter ended September 30, 2026); management expects it to fund operations into the second quarter of 2027. The prior quarter's 10-Q had said into the first quarter of 2027.",
   "accepted_variants": [
    "$30.9 million",
    "second quarter of 2027"
   ],
   "as_of": "September 30, 2026; reports filed on or before November 10, 2026",
   "primary_source": [
    {
     "accession": "0001601485-26-000066",
     "form": "10-Q",
     "filing_date": "2026-11-05",
     "url": "https://www.sec.gov/Archives/edgar/data/1601485/000160148526000066/eltx-20260930.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1601485/000160148526000066/",
     "role": "Q3 2026 10-Q"
    },
    {
     "accession": "0001601485-26-000056",
     "form": "10-Q",
     "filing_date": "2026-08-13",
     "url": "https://www.sec.gov/Archives/edgar/data/1601485/000160148526000056/eltx-20260630.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1601485/000160148526000056/",
     "role": "trap: superseded Q2 guidance"
    }
   ],
   "supporting_passage": "[0001601485-26-000066 10-Q 2026-11-05] July 2026 Offering resulted in aggregate net proceeds of approximately $ 13.6 million after deducting the placement agents\u2019 fees and related offering expenses. As of September 30, 2026, the Company had $ 30.9 million in cash and cash equivalents. The Company\u2019s losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for a ||| [0001601485-26-000066 10-Q 2026-11-05] h position and cash runway. As of the filing date of this Quarterly Report on Form 10-Q, we believe that our cash on hand will enable us to fund our operations into the second quarter of 2027 based on our current financial operating plan. This period could be shortened or lengthened if there are any significant increases or decreases in planned or a ||| [0001601485-26-000056 10-Q 2026-08-13] h position and cash runway. As of the filing date of this Quarterly Report on Form 10-Q, we believe that our cash on hand will enable us to fund our operations into the first quarter of 2027 based on our current financial operating plan. This period could be shortened or lengthened if there are any significant increases or decreases in planned or a",
   "supporting_passages": [
    "[0001601485-26-000066 10-Q 2026-11-05] July 2026 Offering resulted in aggregate net proceeds of approximately $ 13.6 million after deducting the placement agents\u2019 fees and related offering expenses. As of September 30, 2026, the Company had $ 30.9 million in cash and cash equivalents. The Company\u2019s losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for a",
    "[0001601485-26-000066 10-Q 2026-11-05] h position and cash runway. As of the filing date of this Quarterly Report on Form 10-Q, we believe that our cash on hand will enable us to fund our operations into the second quarter of 2027 based on our current financial operating plan. This period could be shortened or lengthened if there are any significant increases or decreases in planned or a",
    "[0001601485-26-000056 10-Q 2026-08-13] h position and cash runway. As of the filing date of this Quarterly Report on Form 10-Q, we believe that our cash on hand will enable us to fund our operations into the first quarter of 2027 based on our current financial operating plan. This period could be shortened or lengthened if there are any significant increases or decreases in planned or a"
   ],
   "xbrl_facts": [
    {
     "tag": "CashAndCashEquivalentsAtCarryingValue",
     "value": 30900000,
     "period_start": null,
     "period_end": "2026-09-30",
     "accession": "0001601485-26-000066"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Runway guidance changed between the Q2 10-Q ('into the first quarter of 2027') and the Q3 10-Q ('into the second quarter of 2027'); a tool that relies on the August filing gives stale guidance and a June 30 balance.",
   "difficulty_features": [
    "find newest filing",
    "superseded guidance"
   ],
   "question": "Based on the most recent quarterly report Elicio Therapeutics (ELTX) had filed on or before November 10, 2026: what were its cash and cash equivalents at quarter end, and through when did management say its cash would fund operations?"
  },
  {
   "id": "R3-34",
   "ticker": "NAII",
   "category": "shares_float",
   "answer": "Approximately $22,113,000 as of December 31, 2025 (based on a $3.58 close); 6,264,847 shares outstanding as of September 28, 2026, net of 3,387,059 treasury shares (Form 10-K for fiscal year ended June 30, 2026, filed September 28, 2026).",
   "accepted_variants": [
    "$22,113,000",
    "$22.1 million",
    "6,264,847"
   ],
   "as_of": "Float December 31, 2025; shares September 28, 2026",
   "primary_source": [
    {
     "accession": "0001437749-26-031343",
     "form": "10-K",
     "filing_date": "2026-09-28",
     "url": "https://www.sec.gov/Archives/edgar/data/787253/000143774926031343/naii20260630_10k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/787253/000143774926031343/",
     "role": "FY2026 10-K"
    }
   ],
   "supporting_passage": "[0001437749-26-031343 10-K 2026-09-28]  of NAI\u2019s common stock held by non-affiliates of NAI as of the last business day of NAI\u2019s most recently completed second fiscal quarter (December 31, 2025) was approximately $ 22,113,000 (based on the closing sale price of $3.58 reported by Nasdaq on December 31, 2025). As of September 28, 2026, 6,264,847 shares of NAI\u2019s common stock were outst ||| [0001437749-26-031343 10-K 2026-09-28] December 31, 2025) was approximately $ 22,113,000 (based on the closing sale price of $3.58 reported by Nasdaq on December 31, 2025). As of September 28, 2026, 6,264,847 shares of NAI\u2019s common stock were outstanding, net of 3,387,059 treasury shares. DOCUMENTS INCORPORATED BY REFERENCE Part III (Items 10, 11, 12, 13 and 14) of this Fo ||| [0001437749-26-031343 10-K 2026-09-28] closing sale price of $3.58 reported by Nasdaq on December 31, 2025). As of September 28, 2026, 6,264,847 shares of NAI\u2019s common stock were outstanding, net of 3,387,059 treasury shares. DOCUMENTS INCORPORATED BY REFERENCE Part III (Items 10, 11, 12, 13 and 14) of this Form 10-K incorporates by reference portions of NAI\u2019s definitive proxy stat",
   "supporting_passages": [
    "[0001437749-26-031343 10-K 2026-09-28]  of NAI\u2019s common stock held by non-affiliates of NAI as of the last business day of NAI\u2019s most recently completed second fiscal quarter (December 31, 2025) was approximately $ 22,113,000 (based on the closing sale price of $3.58 reported by Nasdaq on December 31, 2025). As of September 28, 2026, 6,264,847 shares of NAI\u2019s common stock were outst",
    "[0001437749-26-031343 10-K 2026-09-28] December 31, 2025) was approximately $ 22,113,000 (based on the closing sale price of $3.58 reported by Nasdaq on December 31, 2025). As of September 28, 2026, 6,264,847 shares of NAI\u2019s common stock were outstanding, net of 3,387,059 treasury shares. DOCUMENTS INCORPORATED BY REFERENCE Part III (Items 10, 11, 12, 13 and 14) of this Fo",
    "[0001437749-26-031343 10-K 2026-09-28] closing sale price of $3.58 reported by Nasdaq on December 31, 2025). As of September 28, 2026, 6,264,847 shares of NAI\u2019s common stock were outstanding, net of 3,387,059 treasury shares. DOCUMENTS INCORPORATED BY REFERENCE Part III (Items 10, 11, 12, 13 and 14) of this Form 10-K incorporates by reference portions of NAI\u2019s definitive proxy stat"
   ],
   "xbrl_facts": [
    {
     "tag": "EntityCommonStockSharesOutstanding",
     "value": 22113000,
     "period_start": null,
     "period_end": "2026-09-28",
     "accession": "0001437749-26-031343"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "June fiscal year: float is measured at December 31, 2025. The filing's XBRL dei:EntityCommonStockSharesOutstanding fact is 22,113,000 (the dollar float value), so an XBRL-driven tool may report 22.1 million SHARES outstanding; the cover text says 6,264,847.",
   "difficulty_features": [
    "non-calendar fiscal year",
    "XBRL tagging error",
    "cover reading"
   ],
   "question": "According to the most recent annual report Natural Alternatives International (NAII) had filed as of October 31, 2026: what was the aggregate market value of common stock held by non-affiliates (and at what date), and how many shares were outstanding on the cover date?"
  },
  {
   "id": "R3-35",
   "ticker": "HEPA",
   "category": "other_insider",
   "answer": "16,500,000 common shares at $0.05 (about $825,000) across five reporting persons: LoPriore (Executive Chairman) 10,000,000 indirect (8,000,000 + 2,000,000), CEO Appajosyula 2,000,000, CFO Stetz 2,000,000, director Purcell 2,000,000 and director Stetz II 500,000. Each also received an equal number of warrants (16,500,000 in total) exercisable at $0.06, expiring August 3, 2031.",
   "accepted_variants": [
    "16,500,000",
    "$0.05",
    "$825,000"
   ],
   "as_of": "Transaction date August 3, 2026 (Form 4s filed August 12, 2026)",
   "primary_source": [
    {
     "accession": "0001493152-26-037489",
     "form": "4",
     "filing_date": "2026-08-12",
     "url": "https://www.sec.gov/Archives/edgar/data/1583771/000149315226037489/ownership.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1583771/000149315226037489/",
     "role": "Form 4 LoPriore"
    },
    {
     "accession": "0001493152-26-037490",
     "form": "4",
     "filing_date": "2026-08-12",
     "url": "https://www.sec.gov/Archives/edgar/data/1583771/000149315226037490/ownership.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1583771/000149315226037490/",
     "role": "Form 4 Appajosyula"
    },
    {
     "accession": "0001493152-26-037493",
     "form": "4",
     "filing_date": "2026-08-12",
     "url": "https://www.sec.gov/Archives/edgar/data/1583771/000149315226037493/ownership.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1583771/000149315226037493/",
     "role": "Form 4 Purcell"
    },
    {
     "accession": "0001493152-26-037496",
     "form": "4",
     "filing_date": "2026-08-12",
     "url": "https://www.sec.gov/Archives/edgar/data/1583771/000149315226037496/ownership.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1583771/000149315226037496/",
     "role": "Form 4 Stetz"
    },
    {
     "accession": "0001493152-26-037500",
     "form": "4",
     "filing_date": "2026-08-12",
     "url": "https://www.sec.gov/Archives/edgar/data/1583771/000149315226037500/ownership.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1583771/000149315226037500/",
     "role": "Form 4 Stetz II"
    }
   ],
   "supporting_passage": "[0001493152-26-037489 4 2026-08-12] nCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>8000000</value> </transactionShares> <transactionPricePerShare> <value>0.05</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactio ||| [0001493152-26-037489 4 2026-08-12] nCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>2000000</value> </transactionShares> <transactionPricePerShare> <value>0.05</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactio ||| [0001493152-26-037489 4 2026-08-12] ansaction> </nonDerivativeTable> <derivativeTable> <derivativeTransaction> <securityTitle> <value>Warrants</value> </securityTitle> <conversionOrExercisePrice> <value>0.06</value> </conversionOrExercisePrice> <transactionDate> <value>2026-08-03</value> </transactionDate> <deemedExecutionDate></deemedExecutionDate> <transactionCoding> <tr ||| [0001493152-26-037489 4 2026-08-12] ol> <issuerForeignTradingSymbol></issuerForeignTradingSymbol> </issuer> <reportingOwner> <reportingOwnerId> <rptOwnerCik>0001633927</rptOwnerCik> <rptOwnerName>LoPriore Vincent S</rptOwnerName> </reportingOwnerId> <reportingOwnerAddress> <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag> <rptOwnerStreet1>C/O HEPION PHA ||| [0001493152-26-037490 4 2026-08-12] nCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>2000000</value> </transactionShares> <transactionPricePerShare> <value>0.05</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactio ||| [0001493152-26-037490 4 2026-08-12] <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>2000000</value> </transactionShares> <transactionPricePerShare> <value>0.05</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactionAcquiredDisposedCode> </transactionAmounts> <postTransactionAmounts ||| [0001493152-26-037490 4 2026-08-12] ol> <issuerForeignTradingSymbol></issuerForeignTradingSymbol> </issuer> <reportingOwner> <reportingOwnerId> <rptOwnerCik>0001901565</rptOwnerCik> <rptOwnerName>Appajosyula Sireesh</rptOwnerName> </reportingOwnerId> <reportingOwnerAddress> <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag> <rptOwnerStreet1>C/O HEPION PHARM ||| [0001493152-26-037493 4 2026-08-12] nCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>2000000</value> </transactionShares> <transactionPricePerShare> <value>0.05</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactio ||| [0001493152-26-037493 4 2026-08-12] ol> <issuerForeignTradingSymbol></issuerForeignTradingSymbol> </issuer> <reportingOwner> <reportingOwnerId> <rptOwnerCik>0001694934</rptOwnerCik> <rptOwnerName>Purcell Michael J.</rptOwnerName> </reportingOwnerId> <reportingOwnerAddress> <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag> <rptOwnerStreet1>C/O HEPION PH ||| [0001493152-26-037496 4 2026-08-12] nCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>2000000</value> </transactionShares> <transactionPricePerShare> <value>0.05</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactio ||| [0001493152-26-037496 4 2026-08-12] ol> <issuerForeignTradingSymbol></issuerForeignTradingSymbol> </issuer> <reportingOwner> <reportingOwnerId> <rptOwnerCik>0001532793</rptOwnerCik> <rptOwnerName>Stetz Gary S.</rptOwnerName> </reportingOwnerId> <reportingOwnerAddress> <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag> <rptOwnerStreet1>C/O HEPION PHARMACEUTICA ||| [0001493152-26-037500 4 2026-08-12] nCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>500000</value> </transactionShares> <transactionPricePerShare> <value>0.05</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactio ||| [0001493152-26-037500 4 2026-08-12] ol> <issuerForeignTradingSymbol></issuerForeignTradingSymbol> </issuer> <reportingOwner> <reportingOwnerId> <rptOwnerCik>0002145064</rptOwnerCik> <rptOwnerName>Stetz Gary S. II</rptOwnerName> </reportingOwnerId> <reportingOwnerAddress> <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag> <rptOwnerStreet1>C/O HEPION PHARMACEUTICA",
   "supporting_passages": [
    "[0001493152-26-037489 4 2026-08-12] nCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>8000000</value> </transactionShares> <transactionPricePerShare> <value>0.05</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactio",
    "[0001493152-26-037489 4 2026-08-12] nCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>2000000</value> </transactionShares> <transactionPricePerShare> <value>0.05</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactio",
    "[0001493152-26-037489 4 2026-08-12] ansaction> </nonDerivativeTable> <derivativeTable> <derivativeTransaction> <securityTitle> <value>Warrants</value> </securityTitle> <conversionOrExercisePrice> <value>0.06</value> </conversionOrExercisePrice> <transactionDate> <value>2026-08-03</value> </transactionDate> <deemedExecutionDate></deemedExecutionDate> <transactionCoding> <tr",
    "[0001493152-26-037489 4 2026-08-12] ol> <issuerForeignTradingSymbol></issuerForeignTradingSymbol> </issuer> <reportingOwner> <reportingOwnerId> <rptOwnerCik>0001633927</rptOwnerCik> <rptOwnerName>LoPriore Vincent S</rptOwnerName> </reportingOwnerId> <reportingOwnerAddress> <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag> <rptOwnerStreet1>C/O HEPION PHA",
    "[0001493152-26-037490 4 2026-08-12] nCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>2000000</value> </transactionShares> <transactionPricePerShare> <value>0.05</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactio",
    "[0001493152-26-037490 4 2026-08-12] <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>2000000</value> </transactionShares> <transactionPricePerShare> <value>0.05</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactionAcquiredDisposedCode> </transactionAmounts> <postTransactionAmounts",
    "[0001493152-26-037490 4 2026-08-12] ol> <issuerForeignTradingSymbol></issuerForeignTradingSymbol> </issuer> <reportingOwner> <reportingOwnerId> <rptOwnerCik>0001901565</rptOwnerCik> <rptOwnerName>Appajosyula Sireesh</rptOwnerName> </reportingOwnerId> <reportingOwnerAddress> <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag> <rptOwnerStreet1>C/O HEPION PHARM",
    "[0001493152-26-037493 4 2026-08-12] nCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>2000000</value> </transactionShares> <transactionPricePerShare> <value>0.05</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactio",
    "[0001493152-26-037493 4 2026-08-12] ol> <issuerForeignTradingSymbol></issuerForeignTradingSymbol> </issuer> <reportingOwner> <reportingOwnerId> <rptOwnerCik>0001694934</rptOwnerCik> <rptOwnerName>Purcell Michael J.</rptOwnerName> </reportingOwnerId> <reportingOwnerAddress> <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag> <rptOwnerStreet1>C/O HEPION PH",
    "[0001493152-26-037496 4 2026-08-12] nCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>2000000</value> </transactionShares> <transactionPricePerShare> <value>0.05</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactio",
    "[0001493152-26-037496 4 2026-08-12] ol> <issuerForeignTradingSymbol></issuerForeignTradingSymbol> </issuer> <reportingOwner> <reportingOwnerId> <rptOwnerCik>0001532793</rptOwnerCik> <rptOwnerName>Stetz Gary S.</rptOwnerName> </reportingOwnerId> <reportingOwnerAddress> <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag> <rptOwnerStreet1>C/O HEPION PHARMACEUTICA",
    "[0001493152-26-037500 4 2026-08-12] nCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>500000</value> </transactionShares> <transactionPricePerShare> <value>0.05</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactio",
    "[0001493152-26-037500 4 2026-08-12] ol> <issuerForeignTradingSymbol></issuerForeignTradingSymbol> </issuer> <reportingOwner> <reportingOwnerId> <rptOwnerCik>0002145064</rptOwnerCik> <rptOwnerName>Stetz Gary S. II</rptOwnerName> </reportingOwnerId> <reportingOwnerAddress> <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag> <rptOwnerStreet1>C/O HEPION PHARMACEUTICA"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Five Form 4s must be summed; LoPriore's filing has two indirect lines (two entities). Two different people named Gary S. Stetz (CFO and 'II', a director) both filed. The warrants are reported as derivative code P at $0 price.",
   "difficulty_features": [
    "multi-filing (5 Form 4s)",
    "indirect holdings",
    "look-alike names"
   ],
   "question": "On August 3, 2026, Hepion Pharmaceuticals (HEPA) insiders reported open-market purchases (Form 4 code P). In total, how many common shares did they buy, at what price, and what else did they acquire alongside the shares?"
  },
  {
   "id": "R3-36",
   "ticker": "PFSA",
   "category": "reverse_split",
   "answer": "12,320 shares (10-Q for the quarter ended June 30, 2026), reflecting the 1-for-25 split (July 2026) and the 1-for-4 split (August 2026), a combined factor of 100. The February 9, 2026 1-for-75 split is already reflected in the 10-K figure.",
   "accepted_variants": [
    "12,320"
   ],
   "as_of": "December 31, 2025 balance as restated in the 10-Q filed August 19, 2026",
   "primary_source": [
    {
     "accession": "0001213900-26-044046",
     "form": "10-K",
     "filing_date": "2026-04-15",
     "url": "https://www.sec.gov/Archives/edgar/data/1859807/000121390026044046/ea0282813-10k_profusa.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1859807/000121390026044046/",
     "role": "original figure"
    },
    {
     "accession": "0001213900-26-075502",
     "form": "8-K",
     "filing_date": "2026-07-06",
     "url": "https://www.sec.gov/Archives/edgar/data/1859807/000121390026075502/ea0297130-8k_profusa.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1859807/000121390026075502/",
     "role": "split 2"
    },
    {
     "accession": "0001213900-26-089362",
     "form": "8-K",
     "filing_date": "2026-08-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1859807/000121390026089362/ea030148402-8k_profusa.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1859807/000121390026089362/",
     "role": "split 3"
    },
    {
     "accession": "0001213900-26-091696",
     "form": "10-Q",
     "filing_date": "2026-08-19",
     "url": "https://www.sec.gov/Archives/edgar/data/1859807/000121390026091696/ea0300132-10q_profusa.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1859807/000121390026091696/",
     "role": "restated figure"
    }
   ],
   "supporting_passage": "[0001213900-26-044046 10-K 2026-04-15] es issued and outstanding at December 31, 2025 and 2024 \u2014 \u2014 Common stock: $ 0.0001 par value \u2013 600,000,000 authorized shares at December 31, 2025 and 2024, and 1,232,052 and 25,844 shares issued and outstanding at December 31, 2025 and 2024, respectively \u2014 \u2014 Additional paid-in capital 134,123 5,753 Accumulated deficit ( 160,781 ||| [0001213900-26-044046 10-K 2026-04-15] ares. EXPLANATORY NOTE On February 9, 2026, Profusa, Inc. effected a reverse stock split of all shares of its issued and outstanding common stock at a ratio of one-for-seventy five (1:75). The Company accounted for the reverse stock split on a retrospective basis pursuant to Accounting Standards Codification (\u201cASC\u201d) 260, Earnings Per Share. All  ||| [0001213900-26-075502 8-K 2026-07-06] ock split ratio, and such other changes as may be required to effectuate the reverse stock split. Accordingly, the Company\u2019s Chief Executive Officer approved a one-for-twenty-five (1:25) reverse stock split (the \u201cReverse Stock Split\u201d) of the Company\u2019s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with t ||| [0001213900-26-089362 8-K 2026-08-14] y announced that it \ufb01led an amendment to its amended and restated certi\ufb01cate of incorporation with the Secretary of State of the State of Delaware to e \ufb00 ect a one-for-four (1:4) reverse stock split of its common stock. The reverse stock split will take e \ufb00 ect at 12:01 am (Eastern Time) on August 17, 2026, and the Company\u2019s common stock will open for trad ||| [0001213900-26-091696 10-Q 2026-08-19] outstanding at June 30, 2026 and December 31, 2025 \u2014 \u2014 Common stock: $ 0.0001 par value \u2013 600,000,000 authorized shares at June 30, 2026 and December 31, 2025; 132,308 and 12,320 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively \u2014 \u2014 Additional paid-in capital 145,865 134,123 Accumulated deficit ( 172,992 ) ( 160,781 ) Total stockholders\u2019 deficit ( 27,127 ) ( 26,658 ) Tota",
   "supporting_passages": [
    "[0001213900-26-044046 10-K 2026-04-15] es issued and outstanding at December 31, 2025 and 2024 \u2014 \u2014 Common stock: $ 0.0001 par value \u2013 600,000,000 authorized shares at December 31, 2025 and 2024, and 1,232,052 and 25,844 shares issued and outstanding at December 31, 2025 and 2024, respectively \u2014 \u2014 Additional paid-in capital 134,123 5,753 Accumulated deficit ( 160,781",
    "[0001213900-26-044046 10-K 2026-04-15] ares. EXPLANATORY NOTE On February 9, 2026, Profusa, Inc. effected a reverse stock split of all shares of its issued and outstanding common stock at a ratio of one-for-seventy five (1:75). The Company accounted for the reverse stock split on a retrospective basis pursuant to Accounting Standards Codification (\u201cASC\u201d) 260, Earnings Per Share. All ",
    "[0001213900-26-075502 8-K 2026-07-06] ock split ratio, and such other changes as may be required to effectuate the reverse stock split. Accordingly, the Company\u2019s Chief Executive Officer approved a one-for-twenty-five (1:25) reverse stock split (the \u201cReverse Stock Split\u201d) of the Company\u2019s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with t",
    "[0001213900-26-089362 8-K 2026-08-14] y announced that it \ufb01led an amendment to its amended and restated certi\ufb01cate of incorporation with the Secretary of State of the State of Delaware to e \ufb00 ect a one-for-four (1:4) reverse stock split of its common stock. The reverse stock split will take e \ufb00 ect at 12:01 am (Eastern Time) on August 17, 2026, and the Company\u2019s common stock will open for trad",
    "[0001213900-26-091696 10-Q 2026-08-19] outstanding at June 30, 2026 and December 31, 2025 \u2014 \u2014 Common stock: $ 0.0001 par value \u2013 600,000,000 authorized shares at June 30, 2026 and December 31, 2025; 132,308 and 12,320 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively \u2014 \u2014 Additional paid-in capital 145,865 134,123 Accumulated deficit ( 172,992 ) ( 160,781 ) Total stockholders\u2019 deficit ( 27,127 ) ( 26,658 ) Tota"
   ],
   "xbrl_facts": [
    {
     "tag": "CommonStockSharesIssued",
     "value": 1232052,
     "period_start": null,
     "period_end": "2025-12-31",
     "accession": "0001213900-26-044046"
    },
    {
     "tag": "CommonStockSharesOutstanding",
     "value": 1232052,
     "period_start": null,
     "period_end": "2025-12-31",
     "accession": "0001213900-26-044046"
    },
    {
     "tag": "CommonStockSharesIssued",
     "value": 12320,
     "period_start": null,
     "period_end": "2025-12-31",
     "accession": "0001213900-26-091696"
    },
    {
     "tag": "CommonStockSharesOutstanding",
     "value": 12320,
     "period_start": null,
     "period_end": "2025-12-31",
     "accession": "0001213900-26-091696"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Three 2026 splits; applying all three (factor 7,500) to the 10-K number double-counts the February 1-for-75 split that the 10-K already reflects (gives about 164). Each 8-K quotes a 1-for-5 to 1-for-200 range before the chosen ratio.",
   "difficulty_features": [
    "split-adjusting an old figure",
    "avoid double-applying earlier split",
    "multi-filing"
   ],
   "question": "Profusa (PFSA) reported 1,232,052 shares of common stock issued and outstanding at December 31, 2025 in its FY2025 Form 10-K. After the reverse splits it effected later in 2026, what is that December 31, 2025 figure as restated in its later quarterly report, and which splits caused the change?"
  },
  {
   "id": "R3-37",
   "ticker": "NXTC",
   "category": "cash",
   "answer": "$8.7 million at September 30, 2026 (10-Q for the quarter ended September 30, 2026); management expects it to fund operations into early 2027. The prior quarter's 10-Q had said into the fourth quarter of 2026.",
   "accepted_variants": [
    "$8.7 million",
    "early 2027"
   ],
   "as_of": "September 30, 2026; reports filed on or before November 10, 2026",
   "primary_source": [
    {
     "accession": "0001104659-26-125220",
     "form": "10-Q",
     "filing_date": "2026-11-10",
     "url": "https://www.sec.gov/Archives/edgar/data/1661059/000110465926125220/nxtc-20260930x10q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1661059/000110465926125220/",
     "role": "Q3 2026 10-Q"
    },
    {
     "accession": "0001104659-26-092050",
     "form": "10-Q",
     "filing_date": "2026-08-06",
     "url": "https://www.sec.gov/Archives/edgar/data/1661059/000110465926092050/nxtc-20260630x10q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1661059/000110465926092050/",
     "role": "trap: superseded Q2 guidance"
    }
   ],
   "supporting_passage": "[0001104659-26-125220 10-Q 2026-11-10] nd has an accumulated deficit of $ 468 million as of September 30, 2026. Under the Company's current plan, management believes its cash and cash equivalents of $ 8.7 million as of September 30, 2026 will only be sufficient to fund the Company's operations into early 2027. The Company will require additional funding to sustain operations beyond that period  ||| [0001104659-26-125220 10-Q 2026-11-10] rent plan, management believes its cash and cash equivalents of $ 8.7 million as of September 30, 2026 will only be sufficient to fund the Company's operations into early 2027. The Company will require additional funding to sustain operations beyond that period and expects to continue generating operating losses for the foreseeable f ||| [0001104659-26-092050 10-Q 2026-08-06] ment believes its cash and cash equivalents and marketable securities of $ 20.1 million as of June 30, 2026 will be sufficient to fund the Company's operations into the fourth quarter of 2026. H owever, the Company will need to obtain additional funding to sustain operations as it expects to continue to generate operating losses for the foreseeable ",
   "supporting_passages": [
    "[0001104659-26-125220 10-Q 2026-11-10] nd has an accumulated deficit of $ 468 million as of September 30, 2026. Under the Company's current plan, management believes its cash and cash equivalents of $ 8.7 million as of September 30, 2026 will only be sufficient to fund the Company's operations into early 2027. The Company will require additional funding to sustain operations beyond that period ",
    "[0001104659-26-125220 10-Q 2026-11-10] rent plan, management believes its cash and cash equivalents of $ 8.7 million as of September 30, 2026 will only be sufficient to fund the Company's operations into early 2027. The Company will require additional funding to sustain operations beyond that period and expects to continue generating operating losses for the foreseeable f",
    "[0001104659-26-092050 10-Q 2026-08-06] ment believes its cash and cash equivalents and marketable securities of $ 20.1 million as of June 30, 2026 will be sufficient to fund the Company's operations into the fourth quarter of 2026. H owever, the Company will need to obtain additional funding to sustain operations as it expects to continue to generate operating losses for the foreseeable "
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Runway guidance changed between the Q2 10-Q ('into the fourth quarter of 2026') and the Q3 10-Q ('into early 2027'); a tool that relies on the August filing gives stale guidance and a June 30 balance.",
   "difficulty_features": [
    "find newest filing",
    "superseded guidance"
   ],
   "question": "Based on the most recent quarterly report NextCure (NXTC) had filed on or before November 10, 2026: what were its cash and cash equivalents at quarter end, and through when did management say its cash would fund operations?"
  },
  {
   "id": "R3-38",
   "ticker": "TGL",
   "category": "shares_float",
   "answer": "Approximately $10.1 million as of December 31, 2025 (based on a $6.13 close); 5,159,897 shares outstanding on October 13, 2026 (Form 10-K for fiscal year ended June 30, 2026).",
   "accepted_variants": [
    "$10.1 million",
    "5,159,897"
   ],
   "as_of": "Float December 31, 2025; shares October 13, 2026",
   "primary_source": [
    {
     "accession": "0001213900-26-109073",
     "form": "10-K",
     "filing_date": "2026-10-13",
     "url": "https://www.sec.gov/Archives/edgar/data/1905956/000121390026109073/ea0306002-10k_treausre.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1905956/000121390026109073/",
     "role": "FY2026 10-K"
    }
   ],
   "supporting_passage": "[0001213900-26-109073 10-K 2026-10-13] f the Registrant as of December 31, 2025 (which is the last business day of Registrant\u2019s most recently completed second fiscal quarter) based upon the reported closing price of $6.13 on The Nasdaq Capital Market on that date, was approximately $ 10.1 million. The number of shares outstanding of the Registrant\u2019s common stock, par value $0.00 ||| [0001213900-26-109073 10-K 2026-10-13] ay of Registrant\u2019s most recently completed second fiscal quarter) based upon the reported closing price of $6.13 on The Nasdaq Capital Market on that date, was approximately $ 10.1 million. The number of shares outstanding of the Registrant\u2019s common stock, par value $0.00001 per share, on October 13, 2026 was 5,159,897 shares. Table of Contents P ||| [0001213900-26-109073 10-K 2026-10-13] ate, was approximately $ 10.1 million. The number of shares outstanding of the Registrant\u2019s common stock, par value $0.00001 per share, on October 13, 2026 was 5,159,897 shares. Table of Contents Page PART I 1 Item 1. Business 1 Item 1A. Risk Factors 19 Item 1B. Unresolved Staff Comments 36 Item 1C. Cybersecurity 36 Item 2. Properties ||| [0001213900-26-109073 10-K 2026-10-13] TOTAL LIABILITIES 5,751,860 4,129,415 COMMITMENTS AND CONTINGENCIES - - STOCKHOLDERS\u2019 EQUITY Common stock, par value $ 0.00001 ; 600,000,000 shares authorized, 2,027,579 and 207,470 shares issued and outstanding as of June 30, 2026 and 2025, respectively* 21 2 Additional paid-in capital* 85,997,437 72,023,291 Accumulated deficit ( 72,492,602 ) ( 61,407,562 ) Accumulate",
   "supporting_passages": [
    "[0001213900-26-109073 10-K 2026-10-13] f the Registrant as of December 31, 2025 (which is the last business day of Registrant\u2019s most recently completed second fiscal quarter) based upon the reported closing price of $6.13 on The Nasdaq Capital Market on that date, was approximately $ 10.1 million. The number of shares outstanding of the Registrant\u2019s common stock, par value $0.00",
    "[0001213900-26-109073 10-K 2026-10-13] ay of Registrant\u2019s most recently completed second fiscal quarter) based upon the reported closing price of $6.13 on The Nasdaq Capital Market on that date, was approximately $ 10.1 million. The number of shares outstanding of the Registrant\u2019s common stock, par value $0.00001 per share, on October 13, 2026 was 5,159,897 shares. Table of Contents P",
    "[0001213900-26-109073 10-K 2026-10-13] ate, was approximately $ 10.1 million. The number of shares outstanding of the Registrant\u2019s common stock, par value $0.00001 per share, on October 13, 2026 was 5,159,897 shares. Table of Contents Page PART I 1 Item 1. Business 1 Item 1A. Risk Factors 19 Item 1B. Unresolved Staff Comments 36 Item 1C. Cybersecurity 36 Item 2. Properties",
    "[0001213900-26-109073 10-K 2026-10-13] TOTAL LIABILITIES 5,751,860 4,129,415 COMMITMENTS AND CONTINGENCIES - - STOCKHOLDERS\u2019 EQUITY Common stock, par value $ 0.00001 ; 600,000,000 shares authorized, 2,027,579 and 207,470 shares issued and outstanding as of June 30, 2026 and 2025, respectively* 21 2 Additional paid-in capital* 85,997,437 72,023,291 Accumulated deficit ( 72,492,602 ) ( 61,407,562 ) Accumulate"
   ],
   "xbrl_facts": [
    {
     "tag": "EntityCommonStockSharesOutstanding",
     "value": 5159897,
     "period_start": null,
     "period_end": "2026-10-13",
     "accession": "0001213900-26-109073"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "June fiscal year; the June 30, 2026 balance sheet share count (2,027,579) is far below the cover count, so quoting the balance sheet as 'shares outstanding' is wrong for the cover date.",
   "difficulty_features": [
    "non-calendar fiscal year",
    "cover vs balance sheet"
   ],
   "question": "According to the most recent annual report Treasure Global (TGL) had filed as of October 31, 2026: what was the aggregate market value of common stock held by non-affiliates (and at what date), and how many shares were outstanding on the cover date?"
  },
  {
   "id": "R3-39",
   "ticker": "PMTS",
   "category": "other_insider",
   "answer": "556,232 shares bought at $21.50 by five reporting persons (Tricor PMT25 Holdings 525,000; H Sanford Riley 13,953; Nicholas Peters 11,628 indirect; Marc Sheinbaum 4,651; Ravi Mallela 1,000). Parallel49 Equity, ULC reported selling 2,687,921 shares at $20.425 under the September 10, 2026 underwriting agreement.",
   "accepted_variants": [
    "556,232",
    "$21.50",
    "2,687,921"
   ],
   "as_of": "Transaction date September 14, 2026",
   "primary_source": [
    {
     "accession": "0001104659-26-107610",
     "form": "4",
     "filing_date": "2026-09-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1641614/000110465926107610/tm2625418-1_4seq1.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1641614/000110465926107610/",
     "role": "Form 4 Tricor PMT25"
    },
    {
     "accession": "0001317406-26-000006",
     "form": "4",
     "filing_date": "2026-09-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1641614/000131740626000006/wk-form4_1789429555.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1641614/000131740626000006/",
     "role": "Form 4 Riley"
    },
    {
     "accession": "0001654770-26-000004",
     "form": "4",
     "filing_date": "2026-09-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1641614/000165477026000004/wk-form4_1789429346.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1641614/000165477026000004/",
     "role": "Form 4 Peters"
    },
    {
     "accession": "0001605873-26-000004",
     "form": "4",
     "filing_date": "2026-09-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1641614/000160587326000004/wk-form4_1789429018.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1641614/000160587326000004/",
     "role": "Form 4 Sheinbaum"
    },
    {
     "accession": "0001751947-26-000004",
     "form": "4",
     "filing_date": "2026-09-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1641614/000175194726000004/wk-form4_1789429425.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1641614/000175194726000004/",
     "role": "Form 4 Mallela"
    },
    {
     "accession": "0001655148-26-000004",
     "form": "4",
     "filing_date": "2026-09-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1641614/000165514826000004/form4.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1641614/000165514826000004/",
     "role": "Form 4 Parallel49 (sale)"
    }
   ],
   "supporting_passage": "[0001104659-26-107610 4 2026-09-14] nCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>525000</value> </transactionShares> <transactionPricePerShare> <value>21.50</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transacti ||| [0001104659-26-107610 4 2026-09-14]  <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>525000</value> </transactionShares> <transactionPricePerShare> <value>21.50</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactionAcquiredDisposedCode> </transactionAmounts> <postTransactionAmounts ||| [0001317406-26-000006 4 2026-09-14] nsactionFormType> <transactionCode>P</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>13953</value> </transactionShares> <transactionPricePerShare> <value>21.50</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transacti ||| [0001654770-26-000004 4 2026-09-14] nsactionFormType> <transactionCode>P</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>11628</value> </transactionShares> <transactionPricePerShare> <value>21.50</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transacti ||| [0001605873-26-000004 4 2026-09-14] nsactionFormType> <transactionCode>P</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>4651</value> </transactionShares> <transactionPricePerShare> <value>21.50</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transacti ||| [0001751947-26-000004 4 2026-09-14] nsactionFormType> <transactionCode>P</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>1000</value> </transactionShares> <transactionPricePerShare> <value>21.50</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transacti ||| [0001655148-26-000004 4 2026-09-14] nsactionCode>S</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> <footnoteId id=\"F1\"/> </transactionCoding> <transactionAmounts> <transactionShares> <value>2687921</value> <footnoteId id=\"F2\"/> </transactionShares> <transactionPricePerShare> <value>20.425</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <valu ||| [0001655148-26-000004 4 2026-09-14] 1\"/> </transactionCoding> <transactionAmounts> <transactionShares> <value>2687921</value> <footnoteId id=\"F2\"/> </transactionShares> <transactionPricePerShare> <value>20.425</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>D</value> </transactionAcquiredDisposedCode> </transactionAmounts> <postTransactionAmounts ||| [0001655148-26-000004 4 2026-09-14] rectOwnership> </ownershipNature> </nonDerivativeTransaction> </nonDerivativeTable> <footnotes> <footnote id=\"F1\">The shares were sold pursuant to that certain Underwriting Agreement between the Reporting Person, the Issuer and the underwriters named therein, dated September 10, 2026, pursuant to which the Reporting Person sold the shares t",
   "supporting_passages": [
    "[0001104659-26-107610 4 2026-09-14] nCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>525000</value> </transactionShares> <transactionPricePerShare> <value>21.50</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transacti",
    "[0001104659-26-107610 4 2026-09-14]  <transactionTimeliness></transactionTimeliness> <transactionAmounts> <transactionShares> <value>525000</value> </transactionShares> <transactionPricePerShare> <value>21.50</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactionAcquiredDisposedCode> </transactionAmounts> <postTransactionAmounts",
    "[0001317406-26-000006 4 2026-09-14] nsactionFormType> <transactionCode>P</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>13953</value> </transactionShares> <transactionPricePerShare> <value>21.50</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transacti",
    "[0001654770-26-000004 4 2026-09-14] nsactionFormType> <transactionCode>P</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>11628</value> </transactionShares> <transactionPricePerShare> <value>21.50</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transacti",
    "[0001605873-26-000004 4 2026-09-14] nsactionFormType> <transactionCode>P</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>4651</value> </transactionShares> <transactionPricePerShare> <value>21.50</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transacti",
    "[0001751947-26-000004 4 2026-09-14] nsactionFormType> <transactionCode>P</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>1000</value> </transactionShares> <transactionPricePerShare> <value>21.50</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transacti",
    "[0001655148-26-000004 4 2026-09-14] nsactionCode>S</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> <footnoteId id=\"F1\"/> </transactionCoding> <transactionAmounts> <transactionShares> <value>2687921</value> <footnoteId id=\"F2\"/> </transactionShares> <transactionPricePerShare> <value>20.425</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <valu",
    "[0001655148-26-000004 4 2026-09-14] 1\"/> </transactionCoding> <transactionAmounts> <transactionShares> <value>2687921</value> <footnoteId id=\"F2\"/> </transactionShares> <transactionPricePerShare> <value>20.425</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>D</value> </transactionAcquiredDisposedCode> </transactionAmounts> <postTransactionAmounts",
    "[0001655148-26-000004 4 2026-09-14] rectOwnership> </ownershipNature> </nonDerivativeTransaction> </nonDerivativeTable> <footnotes> <footnote id=\"F1\">The shares were sold pursuant to that certain Underwriting Agreement between the Reporting Person, the Issuer and the underwriters named therein, dated September 10, 2026, pursuant to which the Reporting Person sold the shares t"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Six Form 4s filed the same evening: five buys at the public offering price and one large sale by the selling stockholder at the net underwriting price. Netting them, or counting the sale as insider buying, is wrong; the question asks for each side separately.",
   "difficulty_features": [
    "multi-filing (6 Form 4s)",
    "buy vs sell in same event"
   ],
   "question": "On September 14, 2026, what was the total number of CPI Card Group (PMTS) shares that insiders reported BUYING on Form 4 (code P), at what price, and how many shares did selling stockholder Parallel49 Equity report selling that day?"
  },
  {
   "id": "R3-40",
   "ticker": "INV",
   "category": "other_insider",
   "answer": "536,000 shares across four reporting persons (Michael Otworth 231,000 @ $1.5121; James O. Donnally 225,000 @ $1.50, indirect via Our-No Family Holdings; Gregory W. Haskell 50,000 @ $1.512; Bruce Brown 30,000 @ $1.5133). Total about $807,794. The reported prices are weighted averages; footnotes give individual fills from $1.46 to $1.59.",
   "accepted_variants": [
    "536,000",
    "$807,794",
    "$0.81 million",
    "$1.46 to $1.59"
   ],
   "as_of": "Transaction date August 20, 2026 (Form 4s filed August 21, 2026)",
   "primary_source": [
    {
     "accession": "0001628280-26-058332",
     "form": "4",
     "filing_date": "2026-08-21",
     "url": "https://www.sec.gov/Archives/edgar/data/2001557/000162828026058332/wk-form4_1787318256.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/2001557/000162828026058332/",
     "role": "Form 4 Otworth"
    },
    {
     "accession": "0001628280-26-058331",
     "form": "4",
     "filing_date": "2026-08-21",
     "url": "https://www.sec.gov/Archives/edgar/data/2001557/000162828026058331/wk-form4_1787318246.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/2001557/000162828026058331/",
     "role": "Form 4 Donnally"
    },
    {
     "accession": "0001628280-26-058333",
     "form": "4",
     "filing_date": "2026-08-21",
     "url": "https://www.sec.gov/Archives/edgar/data/2001557/000162828026058333/wk-form4_1787318267.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/2001557/000162828026058333/",
     "role": "Form 4 Haskell"
    },
    {
     "accession": "0002001557-26-000156",
     "form": "4",
     "filing_date": "2026-08-21",
     "url": "https://www.sec.gov/Archives/edgar/data/2001557/000200155726000156/wk-form4_1787318569.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/2001557/000200155726000156/",
     "role": "Form 4 Brown"
    }
   ],
   "supporting_passage": "[0001628280-26-058332 4 2026-08-21] nsactionFormType> <transactionCode>P</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>231000</value> </transactionShares> <transactionPricePerShare> <value>1.5121</value> <footnoteId id=\"F1\"/> </transactionPricePerShare> <transactionAcquiredDisposedCode> <valu ||| [0001628280-26-058332 4 2026-08-21] lved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>231000</value> </transactionShares> <transactionPricePerShare> <value>1.5121</value> <footnoteId id=\"F1\"/> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactionAcquiredDisposedCode> </transactionAmounts> < ||| [0001628280-26-058332 4 2026-08-21] eTable> <footnotes> <footnote id=\"F1\">The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.46 to $1.59 . The Reporting Person undertakes to provide to Innventure, Inc. (the &quot;Issuer&quot;), any security holder of the Issuer, or the staff of the Securities an ||| [0001628280-26-058331 4 2026-08-21] nsactionFormType> <transactionCode>P</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>225000</value> </transactionShares> <transactionPricePerShare> <value>1.50</value> <footnoteId id=\"F1\"/> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value> ||| [0001628280-26-058331 4 2026-08-21] lved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>225000</value> </transactionShares> <transactionPricePerShare> <value>1.50</value> <footnoteId id=\"F1\"/> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactionAcquiredDisposedCode> </transactionAmounts> < ||| [0001628280-26-058331 4 2026-08-21] eTable> <footnotes> <footnote id=\"F1\">The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.48 to $1.53. The Reporting Person undertakes to provide to Innventure, Inc. (the &quot;Issuer&quot;), any security holder of the Issuer, or the staff of the Securities and ||| [0001628280-26-058331 4 2026-08-21] within the ranges set forth in this footnote.</footnote> <footnote id=\"F2\">Common stock, par value $0.0001 per share (Common Stock), of the Issuer purchased by Our-No Family Holdings LP. (Our-No Family Holdings). The Reporting Person has voting and investment power over the Common Stock held by Our-No Family Holdings.</footnote> <footnote i ||| [0001628280-26-058333 4 2026-08-21] nsactionFormType> <transactionCode>P</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>50000</value> </transactionShares> <transactionPricePerShare> <value>1.512</value> <footnoteId id=\"F1\"/> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value ||| [0001628280-26-058333 4 2026-08-21] olved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>50000</value> </transactionShares> <transactionPricePerShare> <value>1.512</value> <footnoteId id=\"F1\"/> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactionAcquiredDisposedCode> </transactionAmounts> < ||| [0001628280-26-058333 4 2026-08-21] eTable> <footnotes> <footnote id=\"F1\">The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.46 to $1.59. The Reporting Person undertakes to provide to Innventure, Inc. (the &quot;Issuer&quot;), any security holder of the Issuer, or the staff of the Securities and ||| [0002001557-26-000156 4 2026-08-21] nsactionFormType> <transactionCode>P</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>30000</value> </transactionShares> <transactionPricePerShare> <value>1.5133</value> <footnoteId id=\"F1\"/> </transactionPricePerShare> <transactionAcquiredDisposedCode> <valu ||| [0002001557-26-000156 4 2026-08-21] olved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>30000</value> </transactionShares> <transactionPricePerShare> <value>1.5133</value> <footnoteId id=\"F1\"/> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactionAcquiredDisposedCode> </transactionAmounts> < ||| [0002001557-26-000156 4 2026-08-21] eTable> <footnotes> <footnote id=\"F1\">The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.4602 to $1.55 . The Reporting Person undertakes to provide to Innventure, Inc. (the &quot;Issuer&quot;), any security holder of the Issuer, or the staff of the Securities an",
   "supporting_passages": [
    "[0001628280-26-058332 4 2026-08-21] nsactionFormType> <transactionCode>P</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>231000</value> </transactionShares> <transactionPricePerShare> <value>1.5121</value> <footnoteId id=\"F1\"/> </transactionPricePerShare> <transactionAcquiredDisposedCode> <valu",
    "[0001628280-26-058332 4 2026-08-21] lved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>231000</value> </transactionShares> <transactionPricePerShare> <value>1.5121</value> <footnoteId id=\"F1\"/> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactionAcquiredDisposedCode> </transactionAmounts> <",
    "[0001628280-26-058332 4 2026-08-21] eTable> <footnotes> <footnote id=\"F1\">The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.46 to $1.59 . The Reporting Person undertakes to provide to Innventure, Inc. (the &quot;Issuer&quot;), any security holder of the Issuer, or the staff of the Securities an",
    "[0001628280-26-058331 4 2026-08-21] nsactionFormType> <transactionCode>P</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>225000</value> </transactionShares> <transactionPricePerShare> <value>1.50</value> <footnoteId id=\"F1\"/> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>",
    "[0001628280-26-058331 4 2026-08-21] lved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>225000</value> </transactionShares> <transactionPricePerShare> <value>1.50</value> <footnoteId id=\"F1\"/> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactionAcquiredDisposedCode> </transactionAmounts> <",
    "[0001628280-26-058331 4 2026-08-21] eTable> <footnotes> <footnote id=\"F1\">The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.48 to $1.53. The Reporting Person undertakes to provide to Innventure, Inc. (the &quot;Issuer&quot;), any security holder of the Issuer, or the staff of the Securities and",
    "[0001628280-26-058331 4 2026-08-21] within the ranges set forth in this footnote.</footnote> <footnote id=\"F2\">Common stock, par value $0.0001 per share (Common Stock), of the Issuer purchased by Our-No Family Holdings LP. (Our-No Family Holdings). The Reporting Person has voting and investment power over the Common Stock held by Our-No Family Holdings.</footnote> <footnote i",
    "[0001628280-26-058333 4 2026-08-21] nsactionFormType> <transactionCode>P</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>50000</value> </transactionShares> <transactionPricePerShare> <value>1.512</value> <footnoteId id=\"F1\"/> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value",
    "[0001628280-26-058333 4 2026-08-21] olved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>50000</value> </transactionShares> <transactionPricePerShare> <value>1.512</value> <footnoteId id=\"F1\"/> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactionAcquiredDisposedCode> </transactionAmounts> <",
    "[0001628280-26-058333 4 2026-08-21] eTable> <footnotes> <footnote id=\"F1\">The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.46 to $1.59. The Reporting Person undertakes to provide to Innventure, Inc. (the &quot;Issuer&quot;), any security holder of the Issuer, or the staff of the Securities and",
    "[0002001557-26-000156 4 2026-08-21] nsactionFormType> <transactionCode>P</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>30000</value> </transactionShares> <transactionPricePerShare> <value>1.5133</value> <footnoteId id=\"F1\"/> </transactionPricePerShare> <transactionAcquiredDisposedCode> <valu",
    "[0002001557-26-000156 4 2026-08-21] olved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>30000</value> </transactionShares> <transactionPricePerShare> <value>1.5133</value> <footnoteId id=\"F1\"/> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactionAcquiredDisposedCode> </transactionAmounts> <",
    "[0002001557-26-000156 4 2026-08-21] eTable> <footnotes> <footnote id=\"F1\">The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.4602 to $1.55 . The Reporting Person undertakes to provide to Innventure, Inc. (the &quot;Issuer&quot;), any security holder of the Issuer, or the staff of the Securities an"
   ],
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Four Form 4s must be summed and each price is a weighted average whose true range is only in the footnotes. Donnally's purchase is indirect (a family LP), and his later Form 4s show other indirect lines that are not part of this purchase.",
   "difficulty_features": [
    "multi-filing (4 Form 4s)",
    "footnote reading",
    "weighted-average prices"
   ],
   "question": "On August 20, 2026, several Innventure (INV) insiders reported open-market purchases on Form 4. How many shares did they buy in total, what was the total reported cost, and what overall per-share price range do the Form 4 footnotes disclose?"
  }
 ]
}